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SONIC HEDGEHOG SIGNALING IN INNER EAR ORGANOID DEVELOPMENT 
 Loss of the finite cochlear hair cells of the inner ear results in 
sensorineural deafness. Human cochlear hair cells do not regenerate, and there 
is no cure for deafness. Our laboratory has established a three-dimensional 
culture system for deriving functional sensory hair cells from human pluripotent 
stem cells. A major limitation of this approach is that derived hair cells exhibit a 
morphological and gene expression phenotype reflective of native vestibular hair 
cells. Previous studies have shown that establishment of localized domains of 
gene expression along the dorso-ventral axis of the developing otic vesicle is 
necessary for proper morphogenesis of both auditory and vestibular inner ear 
structures. Sonic hedgehog (SHH) signaling has been shown to play a key role in 
specification of the ventral otic vesicle and subsequent cochlear development. 
Here, SHH treatment was pursued as a potential strategy for inducing a 
patterning phenotype permissive to cochlear induction in vitro. Single-cell RNA-
sequencing analysis revealed that while treatment with the SHH pathway agonist 
Purmorphamine reduced expression of markers for the vestibular-yielding dorsal 
otic vesicle, upregulation of ventral otic marker genes was modest. More 
strikingly, the number of otic progenitors exhibiting a neuroprogenitor phenotype 
increased in response to Purmorphamine treatment. These results suggest that 
SHH pathway modulation in early-stage inner ear organoids may bias their 
differentiation toward a neural lineage at the expense of an epithelial lineage. 
The present study is the first to evaluate the patterning phenotype of human stem 
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cell derived otic progenitors, and sheds light on the transcriptomic profile at this 
critical point of inner ear development. This study may also cultivate future efforts 
to derive cochlear cell types as well as inner ear neural cell types from human 
pluripotent stem cells, and contribute to the establishment of a more complete in 
vitro model of inner ear development.  
 
   Eri Hashino, Ph.D., Chair 
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CHAPTER ONE: INTRODUCTION 
 Sensorineural hearing loss (SNHL) is caused by the incomplete formation 
or degeneration of mechanosensitive hair cells within the spiral-shaped inner ear 
structure known as the cochlea. This sensory cell population is found in the 
Organ of Corti, a specialized epithelium running through the cochlea, and is 
responsible for converting sound vibrations into electrical signals, a process 
termed mechanotransduction. Loss of the neural population innervating the inner 
ear hair cells, termed spiral ganglion neurons (SGNs), may additionally contribute 
to SNHL. According to a report from the National Institute on Deafness and Other 
Communication Disorders, approximately 15 percent of Americans experience 
noise-induced hearing loss [1], while 2-3 out of every 1,000 children are born with 
profound hearing loss [2]. The current treatment strategies for SNHL focus on the 
amplification of acoustic or electric signals, and do not address the underlying 
pathology, which includes loss of sensory hair cells and SGNs. An in vitro system 
for the derivation of cochlear hair cells from pluripotent stem cells (PSCs) 
represents a potential means to augment or replace this finite cell population. 
Furthermore, such a platform would offer a valuable model for recapitulating the 
pathophysiology of certain types of inner ear disorders.  
 PSCs are capable of self-renewing indefinitely and generating all cell 
types from the three germ layers of the body. Three-dimensional (3D) culture 
systems offer a useful tool for the guided differentiation of PSCs into specific cell 
populations. Culture in a 3D format permits stem cells to interact in a manner that 
more closely mimics in vivo cell-cell and cell-extracellular matrix interactions, 
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allowing for self-organized differentiation, and often facilitating more faithful 
recapitulation of organ development [3-5]. 3D organoid systems have previously 
been employed in the generation of retinal [6, 7], cerebral [8, 9], lung [10], 
intestinal [10, 11], and kidney organoids [12-14], among others, representing a 
platform for disease modeling and drug screening [5, 15-18]. Potential application 
in the development of cell-based therapies is another appealing aspect of these 
systems.  
 Our laboratory has developed a novel 3D in vitro system for generating, 
from mouse and human PSCs, inner ear sensory epithelia, including sensory hair 
cells, supporting cells, and concurrently arising neuronal populations [19, 20]. 
This system employs 3D floating cell culture techniques (described [21]) and 
precisely timed manipulation of several key signaling pathways in order to 
recapitulate inner ear development. However, it is important to note that the 
derived sensory hair cells resulting from this model bear morphological and 
functional properties of the gravity-sensing hair cells of the vestibular end organ 
[19, 20, 22]. Cochlear cell types have not been observed within the system.  
 This lack of cochlear induction has spurred the study described here, 
which set out to investigate the cause of the apparent vestibular bias within this 
model, and to evaluate what factors may lead to the induction of cochlear cell 
types in vitro. The subsequent work focuses primarily on defining the gene 
expression patterns of the early-stage PSC-derived otic progenitors. In vivo, the 
otic vesicle serves as the anlage of the inner ear sensory structures and contains 
multipotent otic progenitors competent to give rise to cochlear or vestibular cell 
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types. Rigorous analysis of the “default state” derived otic vesicle may shed light 
on how to increase efficiency of inner ear sensory cell differentiation, and 
furthermore develop strategies to induce differentiation of cochlear cell types. 
Additionally, one such strategy is investigated here: the introduction of Sonic 
hedgehog (SHH) pathway modulation in the 3D inner ear culture model. SHH 
pathway modulation is evaluated as a potential means to alter the early stage 
gene expression phenotype of the derived otic vesicles and subsequently bias 
differentiation toward a cochlear fate.  
 In order to understand the experimental processes and rationale carried 
out in the subsequent work, I will begin with an overview of several primary areas 
of significance, including inner ear anatomy and development, SHH pathway 
signaling, and a review of previous efforts to model inner ear development in 
vitro. Furthermore, I will discuss single-cell RNA-sequencing, a major component 
of the approaches used in this investigation.   
    
The mammalian ear   
Anatomy and physiology of the human ear      
 The human ear consists of three main areas—the outer, middle, and inner 
ear—each of which contributes to the overall function of the ear in hearing and 
balance (Figure 1). The outer ear consists the pinna and the earlobe, which 
comprise the external portion of the ear, and the external auditory meatus, which 




Figure 1: Anatomy of the human ear.  
The human ear comprises the outer ear, middle ear, and inner ear. The outer ear 
and middle ear function primarily in receiving and transmitting vibrations in the air 
to the inner ear, where mechanical signals are transduced into sensory signals 








The tympanic membrane divides the outer ear and middle ear, and is responsible 
for conveying sound vibrations to the auditory ossicles of the air-filled middle ear. 
The middle ear, or tympanic cavity, contains these three auditory ossicles, known 
as the malleus, incus, and stapes, which serve to convert the mechanical energy 
of sound vibrations in the air to fluid motion within the inner ear.  
 The inner ear contains the auditory-sensing cochlea and the gravity-
sensing vestibular apparatus, the latter of which comprises the semicircular 
canals, saccule, and utricle. Both the cochlea and the vestibular organs house 
sensory epithelia containing mechanosensitive hair cells and non-sensory 
supporting cell types (for review, see [23]) (Figure 2).   
 Within the vestibular organs, sensory hair cells are found in patches 
referred to as maculae in the saccule and utricle, and cristae in the semicircular 
canals. These sensory hair cells serve as the receptors for balance, detecting 
angular acceleration (semicircular canals), linear acceleration (saccule), and 
gravity (utricle). Two types of vestibular hair cells, type I and type II, are found 
randomly dispersed throughout the maculae and cristae. Type I and type II 
vestibular hair cells differ with respect to morphology, wherein type I hair cells 
exhibit an amphora or “vase”-shaped tapered morphology, and type II hair cells 
exhibit a cylindrical shape [24]. Additionally, type I and type II hair cells also differ 
with respect to the nature of their synaptic connections; neurons innervating type 
I hair cells exhibit a cup-like or calyx nerve terminal, while type II hair cells are 
contacted with a bouton nerve terminal [24, 25] (Figure 2).  
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 The cochlea is a spiral-shaped structure that houses the hair cell-
containing Organ of Corti (Figure 2). The Organ of Corti contains two types of 
hair cells that function in sound transduction and are designated with respect to 
their relative positions: inner hair cells (IHCs) are found in one continuous row 
lining the spiral of the Organ of Corti, and outer hair cells (OHCs) are organized 
in three rows adjacent to the inner hair cells. Morphologically, IHCs exhibit a 
pear-like shape, whereas OHCs exhibit a longer, “cigar”- like shape [26].  
 All hair cell types, both vestibular and cochlear, possess epithelial 
protrusions termed hair bundles that are required for their function. Hair bundles 
consist of groups of highly organized structures called stereocilia that are found 
grouped together on the apical surface of the hair cell. The organization of these 
hair bundles may additionally be used to distinguish between cochlear and 
vestibular hair cells. Both type I and type II vestibular hair cells contain hair 
bundles with stereocilia organized from shortest to tallest, with a single motile 
kinocilium at the highest length of the bundle. Cochlear hair cells lack a 
kinocilium, and display stereocilia organized in several rows of ascending height.  
 These hair bundles play an essential role in mechanosensory 
transduction. In the cochlea, hair cells are affixed to the basilar membrane, with 
their stereocilia contacting a structure termed the tectorial membrane. Sound 
waves are transmitted from the auditory ossicles through the round window, and 
translated into fluid waves within the cochlea. These waves cause flexion of the 
basilar membrane, which in turn causes the stereocilia attached to the tectorial  




Figure 2: Vestibular and cochlear sensory hair cells and synaptic innervation.  
 
(a) Type I and type II hair cells exhibit random organization in the sensory 
patches of the vestibular organs. Within the saccule and utricle, hair bundles 
contact an otoconial membrane, which functions in hair cell 
mechanotransduction. Synaptic innervation to efferent vestibular ganglion 
neurons may resemble calyx or bouton morphology. (b) Within the cochlea, hair 
cells are organized into one row of inner hair cells flanked by three rows of outer 
hair cells. Each inner hair cell is contacted by multiple spiral ganglion neurons, 
whereas one spiral ganglion neuron may synapse on multiple outer hair cells. For 
(a) and (b), efferent connections are illustrated in green.   
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membrane to bend. This movement results in the opening of a gated ion channel 
within the hair cell, which triggers depolarization and subsequent signal 
transmission to the cochlear nerve. Within the vestibular organs synaptic 
transmission occurs in a similar manner, with mechanical movement, i.e. head 
rotation, leading to deflection of the stereociliary bundles of hair cells. This 
deflection results in depolarization, and subsequent synaptic transmission to 
neurons of the vestibular ganglion.  
 The neural population associated with the sensory hair cells of the cochlea 
and the vestibular organs differs, with vestibular ganglion neurons (VGNs) 
synapsing on hair cells in the vestibular apparatus, and spiral ganglion neurons 
(SGNs) contacting hair cells in the cochlea. Both VGNs and SGNs are bipolar 
primary afferent neurons, the axons of which make up the VIIIth cranial nerve, 
also known as the cochleo-vestibular nerve. This nerve is responsible for relaying 
auditory and balance information to higher centers of the brain. For the process 
of afferent cochlear transmission, signals are initially relayed from SGNs to 
secondary sensory neurons in the cochlear nuclei in the brainstem (Figure 3). 
From the cochlear nuclei, sound information is transmitted through a series of 
relay centers including the superior olive, the inferior colliculus, and the medial 
geniculate body, before reaching the auditory cortex.  
 
Inner ear development   
 The inner ear is an ectodermally-derived structure. During embryonic 
development, the definitive ectoderm specifies into neural and non-neural  
9 
      
 
Figure 3: Auditory neural pathway from the inner ear. 
Spiral ganglion neurons innervate sensory cells of the cochlea and contribute to 
the VIIIth cranial nerve, which synapses in the cochlear nucleus. The ascending 
pathway includes relays in the superior olive, inferior colliculus, and medial 
geniculate body before reaching the auditory cortex.  
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ectoderm, the latter of which gives rise to the sensory placodes that serve as the 
anlage for structures of the cranial sensory ganglia, including the otic, lens, and 
olfactory placodes (for review, [27]). In humans, the otic placode is characterized 
as a thickened region of surface ectoderm adjacent to the hindbrain. The otic 
placode invaginates to form the otic pit, which pinches off to form a structure 
referred to as the otocyst or otic vesicle. Otic vesicle formation occurs during 
week 4 of pregnancy in humans [28].  
 Precise patterning of the otic vesicle is responsible for establishing 
sensory and non-sensory domains and morphogenesis of the inner ear 
structures [29-31]. Several key signaling pathways are involved in specification of 
the dorsal and ventral regions of the otic vesicle, and will be discussed at length 
further in this introduction. The vestibular apparatus arises from a more dorsal 
aspect of the otic vesicle, whereas the cochlea first appears as an outgrowth 
from the ventral aspect of the otic vesicle. Vestibular development precedes 
cochlear development, with semicircular canal formation and enlargement of the 
vestibule, which gives rise to the saccule and utricle, beginning at embryonic 
week 5  [32]. By week 7, formation of the sensory cristae associated with each 
semicircular canal is evident, coinciding with partitioning of the saccular macula 
and the utricular macula [32]. Vestibular hair cell development occurs between 
weeks 8-9, with nascent stereocilia bundles evident at week 8.   
 Cochlear outgrowth from the ventral otic vesicle is evident at week 5, and 
continues over the next several weeks, with rotation to form the characteristic 2.5 
turns of the cochlea occurring between weeks 8-9. Growth continues until 
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approximately weeks 18-19, when cochlear size reaches that of the adult form. 
Cochlear hair cell development occurs two weeks later than vestibular hair cell 
development, with nascent hair cells first observed during weeks 11-12. IHC 
development occurs first at week 12, with OHC development following. All three 
rows of OHCs are evident by week 14.   
 The cochleovestibular ganglion arises as a population of neural 
progenitors termed neuroblasts that delaminate from the antero-ventral portion of 
the otic vesicle. VGNs are first observed in humans at embryonic week 4. Nerve 
fibers from VGNs begin to extend toward the brain stem at week 5, and enter the 
putative vestibulum at week 6, with afferent nerve fibers observed contacting 
vestibular hair cells during weeks 8-9. SGN development succeeds that of VGN 
development, with the first observations of SGNs during week 8 of embryonic 
development [33].  
 Figure 4 illustrates a timeline for key hallmarks of inner ear sensory 
development, and additionally features specific markers indicative of each of 
these developmental timepoints (Figure 4).  
 
Modeling inner ear development in vitro 
 Efforts toward modeling inner ear cell types in vitro have taken many 
approaches, among them guided differentiation strategies to induce sensory cell 
types by recapitulating the hallmarks of inner ear development. PSCs serve as 
the foundation for these efforts, due to their capacity to differentiate into 





Figure 4: Timeline and key markers of otic cell type induction. 
Developmental timeline for inner ear development, including specific markers 
expressed for each timepoint/cell type. dpc = days post conception.     
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recapitulates inner ear development through the aggregation of PSCs  and 
introduction of signaling cues necessary to induce an inner ear hair cell-specific 
developmental program. Prior to a review of the previous efforts to generate 
inner ear cell types in vitro, I will detail the protocol our lab has employed toward 
this effort, beginning with an exploration of stem cells as a model system.  
 
Pluripotent stem cells   
 Stem cells are defined by the properties of 1) infinite self-renewal, 
meaning the ability to divide and proliferate long-term, and 2) pluripotency, 
meaning the capacity to differentiate into specialized cell types from all three 
germ layers of the body (mesoderm, endoderm, and ectoderm). There are two 
types of PSCs: embryonic stem cells (ESCs) and induced pluripotent stem cells 
(iPSCs).  
 ESCs are derived from the inner cell mass of the blastocyst of the pre-
implantation embryo. A battery of transcription factors, including OCT4, SOX2, 
and NANOG, function in maintaining pluripotency of these cells [34, 35]. iPSCs 
are terminally differentiated somatic cells that have been re-programmed to a 
pluripotent state through the introduction of specific transcription factors. In a 
landmark series of papers by Takahashi and Yamanaka, mouse and human 
adult fibroblasts were re-programmed to a pluripotent state by the introduction of 
OCT4 and SOX2, along with pluripotency markers C-MYC and KLF4, via 
retroviral vectors [36, 37]. The resulting iPSCs resembled ESCs with respect to 
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morphology, proliferative capacity, and transcriptional profile, and furthermore 
were capable of differentiating into cell types of the three germ layers [36].  
 Pluripotency may be characterized by either a naive or primed state. 
Naive state stem cells are equivalent to cells of the inner cell mass that exhibit 
stable pluripotency and express so-called pluripotency markers. Primed state 
stem cells are equivalent to cells of the epiblast that are capable of self-renewal 
and differentiation, but are considered to be more readily “primed” to differentiate 
than naïve state stem cells. Human ESCs are considered to exhibit a primed 
state, akin to mouse epiblast stem cells, rather than a naïve state [38, 39]. 
Accordingly, culture of inner ear organoids from human ESCs requires 
modification from our laboratory’s original published mouse inner ear organoid 
protocol [20], potentially due to these differences in initial “ground state” of the 
stem cells. 
 
Differentiation of human 3D inner ear organoids 
 The generation of human 3D inner ear organoids begins with the 
aggregation of human PSCs. For the purposes of this study, the term “aggregate” 
will be used to describe a single 3D mass of aggregated cells, whereas the term 
inner ear “organoid” will refer to the vesicle-like structures within the aggregates 
in which otic tissue arises. One aggregate may give rise to multiple inner ear 
organoids.  
 Floating stem cell culture techniques were pioneered by Sasai and 
colleagues in a series of landmark papers published in the mid-to-late 2000s [21, 
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40, 41]. Watanabe et al first demonstrated the aggregation of mouse ESCs for 
the differentiation of telencephalic progenitors in a process termed serum-free 
culture of embryoid-like bodies (SFEB) [40]. Under the original SFEB protocol, 
spontaneous aggregation of mouse ESCs into embryoid bodies occurred 
following 1-2 days in suspension or “floating” culture. After eight days in floating 
culture, embryoid bodies were then plated in Petri dishes for two days of 
adherent culture, and induction of telencephalic progenitor cell types was 
observed. This process was later adapted for use with human PSCs, where the 
noted addition of Rho-associated kinase (ROCK) inhibitor Y-27632 promoted 
survival and aggregation of human PSCs [41].  
 Eiraku et al optimized the SFEB protocol by introducing the concept of 
aggregating mouse ESCs in low-adhesion U-bottom 96-well plates [21]. The low-
adhesion properties combined with the U-shaped format of the wells prevented 
cells from adhering to the culture dish, thereby encouraging aggregation. This 
modification to the SFEB format allowed for the formation of embryoid bodies in a 
matter of hours, as compared to days in the Watanabe et al protocols [21]. The 
modified protocol also served to increase the efficiency of differentiation, as 
evidence by an increased number of cells expressing telencephalic progenitor 
markers as compared to the previous SFEB study [40]; furthermore, self-
organization and a more complex degree of differentiation were observed. The 
optimized method, termed SFEBq for the “quick” aggregation step, would serve 
as the foundation for many organoid studies in years to come, including the inner 
ear organoid protocol pioneered by our laboratory [20].  
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 For the generation of inner ear organoids from human PSCs, cells are 
initially aggregated in V-bottom plates, a modification to the SFEBq method [21] 
that was found to promote aggregate formation using human WA25 ESCs [19]. 
Following two days of culture in the V-bottom format, aggregates are transferred 
to U-bottom plates in chemically defined medium (CDM) containing extracellular 
matrix compound Matrigel to promote epithelialization and TGF-β inhibitor in 
order to induce formation of non-neural ectoderm. Subsequent treatments with 
small molecules for activation of Fibroblast Growth Factor (FGF) signaling  and 
inhibition of Bone Morphogenic Protein (BMP) signaling are applied on culture 
day 4 in order to specify pre-placodal ectoderm, and WNT pathway agonist is 
applied on culture day 8 to help promote induction of the otic placode. Additional 
treatment with WNT agonist at culture day 11 promotes otic vesicle induction 
[19]. Following transfer to a long-term culture format on day 18, no additional 
treatments are applied, and induction of sensory and supporting cell populations 
occurs in a self-directed manner. Hair cells are typically observed between day 
40 to day 60 of culture, typified by expression of hair cell markers MYO7A, 
ATOH1, and POU4F3 [19].  
 It is important to note that characterization of the derived hair cells arising 
in this system has corresponded with properties of vestibular type I and type II 
hair cells [19]. Hair cells arising in mouse inner ear organoids exhibit expression 
of vestibular marker Calbindin-2 (Calb2), and extensive electrophysiological 
analysis has revealed derived mouse hair cells appear to be comparable to hair 
cells of the post-natal mouse utricle [22]. Additionally, derived stereocilia bundles 
17 
exhibit a vestibular morphology, and observed synaptic connections appear to 
mirror the calyx or bouton-like synapse observed at nerve terminals of vestibular 
type I and type II hair cells. In the derived hair cells of human inner ear 
organoids, expression of CALB2 has also been observed, along with hair bundle 
morphology similar to that of vestibular hair bundles, with a single acetylated-
alpha-Tubulin (TUBA4A) positive kinocilium observed with among apical 
protrusions co-expressing stereocilia markers F-ACTIN and ESPIN. Clusters of 
hair cells are observed in human inner ear organoids, reminiscent of the 
randomized organization of hair cells observed in the maculae and cristae of 
vestibular organs. Functional analysis has additionally indicated that derived hair 
cells exhibited a similar electrophysiological profile to mouse and human 
vestibular organs [19].  
 
Previous in vitro studies for the differentiation of inner ear cell types 
 Previous otic differentiation studies have investigated both direct 
conversion and guided differentiation approaches to inducing inner ear sensory 
hair cells from PSCs. Direct conversion involves the overexpression of cell type-
specific transcription factors that target cell identity toward a particular lineage 
[42]. A study by Costa and colleagues explored the combined expression of hair 
cell  transcription factors Gfi1, Pou4f3, and Atoh1 to induce hair cell 
differentiation in mouse ESCs [43]. Induced hair cells expressed hair cell-specific 
markers and morphology, including the development of hair bundle-like 
protrusions. However, the protrusions displayed heterogeneous morphology and 
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poor organization, indicating incomplete maturation. Notably, the converted cell 
population lacked corresponding induction of a supporting cell population, which 
may be necessary for establishing an environment for proper hair cell induction. 
One advantage to our guided differentiation approach is that a progenitor 
population is not bypassed as in direct conversion, meaning multipotent 
progenitor cells capable of giving rise to both supporting cells and sensory cell 
types are achieved in culture. Accordingly, we have confirmed the appearance of 
a supporting cell population arising in our inner ear organoid model [19, 20].  
 An early guided differentiation study by Li and colleagues demonstrated 
induction of an otic progenitor-like cell population from mouse ESCs using an 
embryoid body culture technique and timed treatment with epidermal growth 
factor (EGF), insulin-like growth factor 1 (IGF-1), and FGF to induce a cell 
population expressing early otic progenitor markers [44]. Further culture induced 
expression of hair cell markers Myo7a, Atoh1 and Brn3c in a small percentage of 
the derived cell population. Oshima et al employed this stepwise guidance 
protocol using mouse ESCs and iPSCs to induce an otic progenitor population, 
and found that co-culture of these cells on mitotically inactivated chicken utricle 
stromal cells was necessary to promote hair cell marker expression and 
acquisition of hair bundle-like protrusions expressing bundle-specific marker 
Espin [45]. As co-culture with stromal cells was shown to be necessary for hair 
cell-like induction in this culture model, this further indicates the potential role of a 
supporting cell population in contributing to hair cell identity.  
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  Ouji et al employed a method for the generation of otic-like cells wherein 
mouse PSCs were first aggregated into embryoid bodies using a hanging drop 
method [46] and then cultured in conditioned medium from bone marrow-derived 
ST2 stromal cells for a subsequent 14 days [47]. The embryoid bodies produced 
cells expressing hair cell markers Atoh1, Myo7a, and Brn3c. A hair cell-like 
morphology was not observed, although this culture method did produce 
rudimentary hair bundle-like protrusions from the surface of hair cell marker-
expressing cells. 
 It is important to note that all of the previously mentioned studies 
employed mouse PSCs. There are fundamental differences between mouse and 
human development [48, 49], and this is apparent in the inner ear. The mouse 
cochlea is not yet mature at birth, whereas the human cochlea is functional by 
embryonic week 20 [50]. These differences may need to be taken into account in 
establishing methods for the generation of inner ear sensory cells. While mouse 
stem cells may be easier to acquire, the generation of inner ear cell types from 
human tissue presents a clearer avenue toward clinical translation, and more 
potent relevance toward human health.   
 Chen et al first developed a guided differentiation model for otic 
differentiation using human ESCs [51]. This protocol employed timed treatments 
of FGF-3 and FGF-10 in early stage culture to produce an otic progenitor 
population capable of giving rise to sensory hair cell-like cells and neurons. The 
derived sensory cells were found to express hair cell markers MYO7A and 
ATOH1, and additionally bore morphological protrusions reminiscent of hair 
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bundles. However, similar to the Costa et al direct conversion study, the 
protrusions did not display morphology consistent with native hair cells [43, 51].  
 Ding and colleagues also developed a protocol for the differentiation of 
otic progenitors from human ESCs employing FGF-3 and FGF-10 pathway 
activation [52]. This study made use of co-culture with mitotically inactivated 
chicken utricle stromal cells to further promote otic induction. The resulting otic 
epithelial progenitors gave rise to hair cell-like cells bearing stereocilia-like 
bundles that exhibited functional capability. However, this group found that co-
culture was indispensable for induction of hair cell-like cells; cells cultured on 
laminin alone and subjected to the same protocol did not yield derived hair cells 
with proper hair cell morphology. Furthermore, derived cells exhibited short 
apical protrusions lacking bundle morphology and organization, and experienced 
a loss of functional capability as well. Chicken utricle stromal cell conditioned 
media supplemented with EGF and retinoic acid was able to rescue some of the 
effects observed in the laminin-cultured cells; however, efficiency of the 
generation of ESPIN-positive cells was low.   
 Unlike these studies, our laboratory’s model represents a 
“developmentally faithful approach” [19], meaning the progression through the 
hallmarks involved in inner ear development occurs, as opposed to forced otic 
progenitor induction occurring without first “passing through” the necessary 
developmental steps. Ohnishi and colleagues employed a stepwise method for 
the induction of inner hair cell-like cells from human iPSCs that similarly 
emphasized induction of non-neural ectoderm, the preplacodal region, and otic 
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placode prior to otic progenitor induction [53]. However, the protocol was lengthy, 
lasting over 70 days, and induction of otic placode cells, defined by expression of 
early otic progenitor marker PAX2, was extremely limited. This translated into low 
sensory cell induction during later stage culture, and only MYO7A was evaluated 
as a hair cell marker. Additionally, stereocilia-like protrusions were not observed 
in all experiments.  
 Ronaghi et al also pursued a guided differentiation model of human ESC 
differentiation, treating with WNT inhibitor and TGF-β antagonist along with IGF-1 
to promote ectodermal induction during the first fifteen days of culture, and a 
combination of sustained FGF activation along with short periods of WNT 
activation and BMP inhibition and subsequent activation during days 15-21 to 
guide induction of otic progenitor markers. Maintenance in decreasing 
concentrations of knockout serum replacement (KSR) over the subsequent 
twenty days in culture led to the induction of cells expressing hair cell markers 
ATOH1 and MYO7A. This protocol did not require co-culture with embryonic 
chicken utricle cells; the authors purported the KSR treatment successfully 
substituted this, and that withdrawing KSR over time led to upregulation of hair 
cell markers. However, the hair cell marker expression was relatively low, 
implying low efficiency of hair cell induction despite a somewhat robust otic 
progenitor population initially observed. 
 Recently, Lahlou et al investigated the effects of Notch pathway 
modulation in monolayer otic differentiation from human iPSCs, finding that 
application of a Notch inhibitor enhanced expression of otic progenitor markers 
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and led to an increase in expression of hair cell markers MYO7A, ATOH1, and 
POU4F3 [54]. This culture system was adapted from the protocol described in 
Chen et al [51], and did not require co-culture or culture in conditioned medium. 
Similar to Ronaghi et al, induction of non-neural ectoderm and pre-placodal 
ectoderm was observed prior to otic induction [55]. The same group 
subsequently published a study describing a monolayer otic differentiation culture 
from human PSCs that boasted an enriched otic sensory progenitor population, 
through the early dual application TGF-β inhibitor and Wnt inhibitor and 
subsequent addition of Wnt agonist [56]. This protocol yielded an increase in the 
PAX2+ cell population compared to previously published methods [51, 56] and 
led to the induction of MYO7A+/POU4F3+ hair cell-like cells. 
 While these studies elucidated strategies for the induction of cells 
expressing generic hair cell markers such as MYO7A and ATOH1, which are 
expressed in both cochlear and vestibular hair cells, it is important to note that 
specific hair cell identity (cochlear vs. vestibular) was not defined. Additionally, 
although several studies employed 3D culture to the extent of embryoid body 
formation [44, 45], none of these studies exhibited the degree of organization 
observed in our 3D inner ear organoid cultures, which yield sensory-cells and 
supporting cells arising concurrently in a self-organized manner. This complexity 
is lacking in the derived cell populations from previously described studies.  
 Recently, Jeong et al published a study proposing a mechanism for the 
generation of inner ear organoids containing cochlear hair cell-like cells from 
human ESCs and iPSCs [57]. This study employed a 3D culture method in which 
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human ESCs or iPSCs are co-cultured on mitotically inactivated mouse 
embryonic fibroblasts prior to the formation of aggregates. Aggregate generation 
occurred in 96-well low adhesion plates, and a series of small molecule 
treatments, including dual BMP/SB and LDN/FGF treatment as outlined in the 
Koehler et al mouse ESC organoid study [48], were performed. Jeong and 
colleagues highlighted the additional inclusion of Rho-kinase inhibitor Y-27632 
and 2-mercaptoethanol until culture day 8 [57]. Aggregates were cultured for up 
to 90 days, with derived otic vesicles observed by culture day 20, comprised of 
cells expressing otic progenitor markers PAX2, SOX2, and SOX9. By day 36, 
expression of F-ACTIN and stereocilia marker ESPIN were observed, and TEM 
revealed kinocilia and microvilli-like protrusions on cells within the derived otic 
vesicles. qPCR analysis confirmed expression of hair cell markers ATOH1 and 
MYO7A at this time point.  
 Derivation of cochlear-specific cell types was reportedly indicated by 
expression of outer hair cell markers PRESTIN and Oncomodulin (OCM), and a 
lack of expression of type II vestibular hair cell marker CALB2 [57]. However, 
OCM is also present in mouse vestibular hair cells [58], and its presence in 
human hair cells—either cochlear or vestibular—has not been documented. 
Curiously, some derived MYO7A+ cells also expressed vestibular supporting cell 
marker Otopetrin-1 (OTOP1). Morphological phenotypes were unclear, with 
observations of a cylindrical cell morphology potentially indicative of type II 
vestibular hair cells or cochlear outer hair cells, and a bulbous cell morphology, 
which may indicate either type I vestibular hair cells or cochlear inner hair cells.  
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 Hair bundles with stereocilia were observed in some organoids, some of 
which included a kinocilia, indicative of vestibular hair cell types, and some of 
which were arranged in a step-wise fashion, indicative of a cochlear hair cell 
phenotype [57]. Additionally, nerve endings were observed, that appeared with 
either “button-like” or calyx terminals, which may indicate type I hair cells 
(vestibular) or cochlear cell types. Further functional characterization revealed 
that uptake of FM1-43FX dye, a styryl pyridinium dye that is often used to assess 
the presence of hair cell mechanotransduction channels [59], occurred in the 
derived cells. However, the functional analysis in this study did not give 
information with respect to the electrophysiological phenotype of the derived hair 
cells. Previous studies performed on mouse and human inner ear organoids 
generated from our group confirmed an electrophysiological phenotype similar to 
that observed in the native mouse utricle [19, 20, 22].  
 Overall, this study is the first in the previously discussed literature to 
assert derivation of cochlear cell types specifically, as opposed to cells co-
expressing generic hair cell markers such as MYO7A and ATOH1. However, 
although expression of OHC-specific marker PRESTIN was observed, the 
analysis and interpretation of additional phenotypic hallmarks were less clear.  
 
Single-cell RNA-sequencing analysis of the inner ear 
 RNA sequencing (RNA-seq) is a powerful tool to evaluate total gene 
expression within a population of cells. The recent advent of single-cell RNA-
sequencing (scRNA-seq) has allowed for the evaluation of the distribution of 
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gene expression across a population of individually assessed cells. This 
technique may serve to inform reprogramming or guided differentiation studies by 
identifying novel markers within a culture system at key time points during 
development that have not previously been interrogated. Before discussing 
several landmark scRNA-seq studies of the inner ear, I will first detail the 
technology.  
 In scRNA-seq, transcriptomes of thousands of individual cells are 
generated simultaneously with the ability to trace gene expression data back to 
each individual cell. This technique differs from bulk RNA-seq, wherein the 
average gene expression patterns of a pooled cell population are assessed. Bulk 
RNA-seq is considered suitable for the assessment of a relatively homogenous 
cell population, whereas scRNA-seq serves as a powerful tool to assess 
transcriptional differences among a heterogeneous cell population, allowing for 
the potential to uncover cell-type specific markers within a specific tissue type or 
cell population.  
 The earliest scRNA-seq study was published by Tang and colleagues [60], 
detailing the sequencing of a single mouse blastomere. Technological advances 
soon allowed for more efficient single-cell analyses within the next several years, 
with the development of microfluidic, droplet-based platforms allowing for the 
sequencing of thousands of cells from a single sample [61]. There are several 
commercially available droplet-based scRNA-seq platforms, including the 
Fluidigm C1 system and 10X Genomics Chromium system. Both of these 
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platforms follow a similar method for generation of single-cell transcriptomes, 
described as follows (for reviews, see [61, 62]).  
 First, the desired cell population is isolated from a target tissue. Cells may 
be subjected to fluorescence activated cell sorting (FACS) in order to isolate a 
desired population by use of antibody staining or a fluorescent reporter. The 
single-cell solution is then loaded into a microfluidics chamber, where cells are 
individually combined into an oil-based droplet containing a barcoded bead 
(Figure 5a). The bead is coated in primers that bind to the poly[A] tails of mRNA, 
and contain molecular barcodes unique to each individual bead, as well as 
unique molecular identifiers (UMIs) that are specific to each primer (Figure 5b). 
The barcode allows for tracing of all the mRNAs back to an individual cell, 
whereas the UMIs allow for identification and quantification of each individual 
mRNA molecule [63]. Cells are lysed in order to capture RNA, and cDNA is 
generated from the mRNA via reverse transcriptase. cDNA is then amplified by 
PCR. The cDNA from each individual cell may then be pooled for subsequent 
sequencing.  
 scRNA-seq has been employed in analysis of the inner ear. A landmark 
paper from Burns and colleagues used scRNA-seq analysis in order to assess 
cells of the inner ear sensory organs from the neonatal mouse inner ear [64]. 
This study employed FACS to isolate sensory and non-sensory cell types from 
the cochlea and vestibular organs and assessed their transcriptomes. This 
analysis revealed candidate markers specific to sensory populations of the 
cochlea and vestibulum, as well as supporting cell types from both areas.   
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Figure 5: Droplet-based single-cell RNA-sequencing.  
(a) In a microfluidics chamber, single cells are combined with individual barcoded 
beads within oil droplets. (b) Each bead contains barcoded primers unique to that 
individual bead, along with unique molecular identifiers (UMIs) to trace individual 
transcripts. A poly(T) tail allows for binding to the poly(A) tails of mRNA.  
  
28 
The study described in this dissertation employs scRNA-seq to assess 
transcriptional profiles of inner ear organoids cultured according to our previously 
published otic differentiation protocol [19], and those additionally exposed to SHH 
pathway modulation during otic vesicle maturation. This novel work thus far 
represents the earliest use of scRNA-seq analysis in human inner ear organoids.  
 
The role of Sonic hedgehog signaling in inner ear development 
 The otic induction studies described previously explored modulation of key 
signaling pathways found to be involved in induction of otic cell types, including 
FGF and Notch signaling. However to date, SHH signaling pathway modulation 
has not been explored as a potential inducer of cochlear cell types in a PSC 
model of inner ear development, despite the key role of SHH in development of 
the cochlea. The following section will detail the SHH pathway, and its role in 
dorso-ventral patterning of the otic vesicle and subsequent cochlear 
development. 
 
Sonic hedgehog signaling pathway 
 The Hedgehog (HH) family of secreted proteins function diversely, with 
roles in patterning and cell fate specification during development, and 
maintenance and proliferation of cell populations during adulthood (for review, 
see [65]. HH was first identified as a result of genetic screens in Drosophila 
melanogaster [66]. Three mammalian homologues were later identified: SHH, 
Indian hedgehog (IHH), and desert hedgehog (DHH). Of these homologues, SHH 
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is the most widely expressed, and has been implicated in patterning of the early 
neural tube, limb development, and in development of the inner ear [65]. IHH, 
which has partial redundancy with SHH, has been shown to regulate bone and 
cartilage development [67], while DHH functions in germ cell development in the 
testis [68] and peripheral nerve sheath formation [69, 70].  
 HH proteins undergo several processing events prior to secretion in the 
cell, including an autoproteolytic cleavage to form an N-terminal signaling peptide 
and a C-terminal fragment with no known signaling activity [71]. The N-terminal 
signaling peptide is modified further by the addition of a cholesterol molecule and 
palmitoyl moiety. In vertebrates, the HH signaling pathway is associated with the 
primary cilium, a microtubule-based protrusion found on the cell surface [72]. The 
HH receptor is a transmembrane protein called Patched-1 (PTCH1). PTCH1 
inhibits another transmembrane protein, Smoothened (SMO), in the absence of 
HH binding, and prevents SMO from entering the primary cilium. When HH ligand 
binds PTCH1, SMO is able to move into the primary cilium and interact with the 
glioma-associated oncogene (GLI) family of transcription factors, comprising 
GLI1, GLI2, and GLI3, which serve as transcriptional mediators of SHH signaling 
(Figure 6).  
 GLI2 and GLI3 play dual roles in activation and repression of target genes 
(for review, see [73]). Bi-functional transcriptional activity is attributed to a C-
terminal activation domain and N-terminal repressor domain. GLI1, which 
contains only a C-terminal activation domain, functions solely in transcriptional 






Figure 6: Hedgehog signaling pathway.  
 
(a) In the absence of Hedgehog (HH), PTCH1 inhibits SMO. GLI transcription 
factors are bound to Suppressor of Fused (SUFU) and are susceptible to 
phosphorylation by PKA, CKI, and GSK3 kinases. Phosphorylated GLI 
undergoes proteolytic processing to its repressor form (GLI-R) which translocates 
into the nucleus and inhibits transcription of SHH target genes. (b) In the 
presence of HH, active SMO moves into the primary cilium and interacts with the 
GLI-SUFU complex. GLI, maintained in its full-length, activator form (GLI-A), 
dissociates from SUFU and enters the nucleus to activate transcription of HH 





full-length (activator) or truncated (repressor) forms into the nucleus to bind GLI 
responsive genes and either initiate or suppress transcription [73]. 
 
Dorso-ventral patterning of the otic vesicle 
 SHH signaling has been shown to play an essential role in patterning of 
the otic vesicle and subsequent cochlear development [29, 31, 74]. During 
development, SHH emanating from the floor plate and notochord functions in 
establishing the dorsal-ventral (DV) axis of the otic vesicle [29, 31] (Figure 7a). 
As stated previously, the vestibular organs arise from the more dorsal portion of 
the otic vesicle, whereas the cochlea emerges as an outcropping of the ventral-
most region of otic vesicle (Figure 7b). Additionally, neurogenic cell types derive 
from the antero-ventral region of the otocyst [29]. Precise gene expression 
patterning of these domains is necessary for proper development of the inner ear 
structures. 
 A study investigating the role of SHH in otic specification in found that otic 
vesicle induction occurred in SHH knockout mouse embryos, but subsequent 
morphogenesis of inner ear structures was significantly disrupted [29]. Otic 
vesicle induction typically occurs by E9.5 in mice, with formation of inner ear 
structures completed by E15.5. Paint-fill analysis of inner ear structures at E15.5  
revealed aberrant morphology in SHH null mutants, with only partially formed 
posterior and anterior semicircular canals and a loss of lateral canal formation. A 
corresponding loss of sensory cell formation was observed in the vestibular 
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Figure 7: SHH signaling in inner ear development.  
(a) SHH in the developing otic vesicle. SHH plays a direct role in ventral gene 
expression, and an indirect role in dorsal gene expression through modulation of 
WNT and BMP signaling from surrounding tissues. (b) The dorsal otic vesicle 
gives rise to the vestibular system, whereas the ventral-most region of the otic 
vesicle gives rise to the auditory organ, the cochlea.(c) Summary of Brown & 
Epstein (2011) and Riccomagno et al (2002) in which conditional inactivation of 
SMO in the inner ear leads to vestibular morphogenesis only with a lack of 
cochlear formation, whereas SHH deletion disrupts inner ear morphogenesis.  
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organs, with disrupted formation of the semicircular canals, as well as the 
utricular and saccular maculae. Additionally, the cochlear duct and 
endolymphatic ducts failed to form in these embryos, with maintenance of an otic 
vesicle-like morphology observed at the ventral-most region at E15.5, indicative 
of a potential halt in developmental progression at the otic vesicle stage.  
 This lack of cochlear formation following loss of SHH signaling led the 
investigators to evaluate the expression of markers of the ventral otic vesicle that 
precede cochlear development. Expression of homeobox transcription factors 
Otx1 and Otx2 was disrupted, with severely reduced Otx1 expression observed 
along with a lack of Otx2 expression. Additionally, transcription factor Pax2, 
which is expressed initially in the otic placode and then temporally restricted to 
ventromedial otic vesicle, was observed at E8.5, but expression was absent in 
the otic vesicles of E9.5 SHH knockout embryos. Further evaluation revealed 
ventral expansion of dorsal marker Dlx5 [29].  
 Interestingly, the cochleovestibular ganglion failed to form in SHH 
knockout embryos [29]. A neuroprogenitor population expressing inner ear neural 
marker Neurod1 was observed in the ventral otic vesicle, but minimal 
delamination of these neural precursors was observed, and the cochleovestibular 
ganglion was absent in E14.5 embryos.  
 This study indicated a potential role for SHH in ventral patterning of the 
otic vesicle. However, the complete loss of SHH during embryonic development 
obscured whether the observed inner ear phenotype in these embryos was due 
to a loss of direct action of SHH signaling on the inner ear, or as an indirect effect 
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of the loss of SHH acting to regulate signaling pathways from surrounding 
tissues. A subsequent study from the same group sought to answer this question 
by generating a mutant mouse in which SHH pathway effector SMO is 
conditionally inactivated in the developing otic epithelium. In this way, SHH 
signaling is still present and acting on the surrounding tissues, but is unable to 
act directly on the inner ear. In these SMO otic epithelium conditional knockout 
(SMOecko ) mice, vestibular structures appeared to form in a wild-type manner, 
while cochlear morphogenesis did not occur [31] (Figure 7c). Examination of 
dorsal and ventral patterns of gene expression in the otic vesicles of these 
embryos showed that dorsal gene expression was maintained in the absence of 
SHH signaling, whereas ventral gene expression was disrupted [31].  
 Within our inner ear organoid model, small molecule treatments 
recapitulate early stage signaling cues involved in the specification of otic 
tissues. However, otic vesicle stage induction has not been closely analyzed, nor 
has the patterning phenotype at this in vitro developmental time point been 
assessed. The studies by Riccomagno and colleagues [29] and Brown & Epstein 
[31] have defined a role for SHH signaling in ventral specification of the otic 
vesicle, and additionally highlighted transcriptional profiles of the dorsal and 
ventral domains established in the developing otic vesicle. A study from 
Durruthy-Durruthy and colleagues detailed scRNA-seq analysis of cells from the 
mouse otocyst and early neural lineage, identifying a discrete cluster expressing 
ventral markers Lfng and Pax2, and another expressing dorsal markers Dlx5 and 
Oc90 [75]. A recent study by Roccio et al has additionally corroborated dorsal 
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and ventral marker expression in humans by performing gene expression 
analysis on human fetal inner ear tissue [76]. Expression of key dorsal and 
ventral markers has not been evaluated within our model, and therefore, it was 
unknown whether this dorso-ventral polarity is established within our model. The 
subsequent study seeks to address this knowledge gap.   
 
Research aims 
 The primary goals of this project are to evaluate the gene expression 
phenotype of otic vesicle stage human stem cell-derived inner ear organoids and 
to investigate SHH signaling as a potential means to specify ventral otic 
derivatives within this in vitro model. The subsequent research sought to answer 
two key questions about inner ear organoid development: 
 1) What underlies the apparent commitment to a vestibular sensory fate 
within this model? 
 2) What factors may be applied in order to bias differentiation of otic 
progenitors toward a cochlear fate? 
 Derived sensory hair cells within our model exhibit a vestibular phenotype 
only, thereby representing only one aspect of the inner ear sensory system. The 
differentiation of cochlear cell types in vitro remains a goal in order to enhance 
the utility of this model as a platform for drug design, toxicity studies, and 
modeling of disorders related to hearing. To date, dorsal and ventral identity has 
not been characterized in human stem cell-derived otic vesicles. I hypothesize 
that bias toward a vestibular fate in derived sensory hair cells may be due to a 
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dorsal gene expression phenotype of the early derived otic vesicle (Figure 8). 
The prolonged application of WNT agonist CHIR99021 in our differentiation 
protocol may underlie this, given the role of WNT signaling in dorsal patterning of 
the otic vesicle [30]. Furthermore, I hypothesize that precise activation of SHH 
signaling, known to play a role in ventralization of the otic vesicle, may promote 
induction of ventral gene expression in the derived otic vesicles, which may bias 
differentiation toward ventral otic derivatives, particularly cochlear cell types, 
within the human inner ear organoid model.  
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Figure 8: Hypothesis.  
This study investigates the hypothesis that vestibular bias in the inner ear 
organoid culture model is due to a dorsalized phenotype of the early derived otic 
vesicle, typified by expression of dorsal genes (several candidate markers listed 
here). Furthermore, modulation of SHH signaling in early stage culture may 
promote expression of ventral markers, subsequently biasing differentiation 






CHAPTER TWO: MATERIALS AND METHODS 
Embryonic stem cell culture 
 WA25 human ESCs were obtained from WiCell. This feeder-free cell line 
does not require a mouse embryonic fibroblast feeder layer to maintain 
pluripotency. ESCs were maintained as described [19]. Prior to passaging, 1 mL 
Dulbecco’s phosphate buffered saline (DPBS) without Calcium and Magnesium 
(Thermo Fisher Scientific, cat. no. 14-190-250) containing 1% recombinant 
human vitronectin (Thermo Fisher Scientific, cat. no. A14700) was added to the 
desired number of wells of a 6-well multi-dish (Thermo Fisher Scientific, cat. no. 
14-832-11) and left at room temperature for one hour under sterile conditions in a 
biosafety cabinet. For passaging, cells were dissociated in 0.5 mM 
Ethylenediaminetetraacetic acid (EDTA) solution for 2-5 minutes at 37C, or until 
visible spaces appeared between cells on the outer edges of colonies, but prior 
to colonies lifting from the surface of the dish. While cells incubated in EDTA 
solution, vitronectin solution was aspirated from the new multi-dish and 2 mL of 
Essential 8 Flex (E8f) medium (Gibco, cat. no. A2858501) containing 100 µg/mL 
Normocin (Invivogen, cat. no. ant-nr-1) and RevitaCell supplement (Gibco, cat. 
no. A26445-01) at a concentration of 1:100 was added to each well. Following 
EDTA incubation, EDTA solution was aspirated from the treated cells. 1 mL E8f 
medium containing Normocin and RevitaCell supplement was then immediately 
added to the cells. Cells were “washed” from the surface of the plate by pipetting 
medium up and down, with care taken not to introduce bubbles into the solution. 
A desired volume of cells was then pipetted into the wells of the new 6-well plate 
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already containing medium. The plate was gently agitated by hand to spread 
cells evenly across the wells, and subsequently stored at 37C. Cells were 
maintained in E8f medium containing RevitaCell supplement for the first 24 hours 
after passaging. At one day post-passaging, medium was aspirated and replaced 
with E8f medium containing Normocin only. Cells were passaged upon reaching 
~70-80% confluency or every 4-5 days, and maintained at 37C in 5% CO2.  
 For the studies described herein, PAX2-2A-nGFP and ATOH1-2A-GFP 
human ESC reporter lines were additionally used. These cell lines contain green 
fluorescent protein (GFP) reporter cassettes driven by expression of otic 
progenitor marker PAX2 (PAX2-2A-nGFP cell line) or hair cell marker ATOH1 
(ATOH1-2A-GFP cell line). The PAX2-2A-nGFP reporter cassette additionally 
contained a nuclear localization signal, so that GFP expression is observed in the 
nucleus. Reporter ESCs were maintained under the same parameters as WA25 
human ESCs. Both reporter lines were previously established using CRISPR-
Cas9 genome editing in WA25 human ESCs; generation of the ATOH1-2A-GFP 
human ESC reporter line was reported in [19].  
  
Signaling molecules and recombinant proteins 
 During otic differentiation of human ESCs, recombinant Human FGF-2 
(bFGF) (Peprotech, cat. no. 100-18B) was used to activate FGF signaling in early 
stage culture [77]. Small molecule TGF-β inhibitor,SB431542 (Stemgent, cat. no. 
04-0010-05), and small molecule BMP pathway inhibitor LDN-193189 (Reprocell, 
cat. no. 04-0074-02), were additionally applied during early stage culture 
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(additional details in the following section). CHIR99021 (Stemgent, cat. no. 04-
0004-02), a small molecule GSK3 inhibitor [16, 78-80], was employed as a Wnt 
pathway agonist. Purmorphamine (Stemgent, cat. no. 04-0009), a small molecule 
agonist for SHH pathway effector SMO [81], was applied for SHH pathway 
activation.  
 
Inner ear organoid differentiation 
 Human PSCs were cultured to the formation of inner ear organoids as 
described [19]. Briefly, cells were aggregated in 96-well low adhesion V-bottom 
plates (Gel Company, cat. no. LCV96) in E8f medium containing Normocin and 
Y-27632 ROCK inhibitor (Stemgent cat. no. 04-0012-02) and placed at 37C in in 
5% CO2. After two days of culture, stem cell aggregates were transferred to 96-
well low adhesion U-bottom plates (Thermo Fisher Scientific, cat. no. 174925) in 
chemically defined medium (CDM) (see Table 1 for ingredients) containing 2% 
Matrigel Growth Factor Reduced Basement Membrane Matrix (Corning, cat.no. 
354230), SB-421542 (10 μM), and bFGF (4 ng/mL). After a subsequent four days 
of incubation, an additional 25 uL of CDM containing bFGF at 250 ng/mL (25 
ng/mL final concentration) and 1 µM LDN-193189 (200 nM final concentration) 
was added to each well of the 96-well plate. Following an additional four days of 
culture, 25 uL of CDM containing WNT agonist CHIR99021 (CH) at a 
concentration of 18 µM (3 µM final concentration when added to the pre-existing 
volume of 125 uL medium per well) was added to each well. After an additional 
3-4 days in culture,, aggregates were transferred to 100mm tissue culture dishes  
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Table 1: Organoid maturation medium (OMM) components  
Component Manufacturer Catalog no. Volume 
Advanced 
DMEM/F12 
Thermo Scientific 12634028 24.5 mL 
Neurobasal Thermo Scientific 21-103-049 24.5 mL 
GlutaMax Thermo Scientific 35-050-061 500 uL 
B27 without 
Vitamin A 
Thermo Scientific 12587010 500 uL 
N2 supplement Thermo Scientific 17502-048 250 uL 
2-
mercaptoethanol 
Thermo Scientific 21985-023 90 uL 
Normocin Invivogen ant-nr-1 100 uL 
 
Table 2: Chemically defined medium (CDM) components 
Component Manufacturer Catalog no. Volume 
Bovine serum 
albumin 
Sigma-Aldrich A1470-10G 0.25 g 
F-12 + GlutaMax Thermo Scientific 12634028 24.7 mL 




Invitrogen 11905-031 500 uL 
Insulin Sigma-Aldrich I9278-5ML 35 uL 
Transferrin Sigma-Aldrich T8158-100MG 37.5 uL 
1-thioglycerol Sigma-Aldrich M1753-100ML 2 uL 
Normocin Invivogen ant-nr-1 100 uL 
 




(Fisher Scientific, cat. no. 08-772B) in organoid maturation medium (OMM) (see 
Table 2 for ingredients) containing 1% Matrigel and CH (3 µM). On culture day 
15, OMM was aspirated and replaced with OMM containing Matrigel + CH (3 µM) 
with a 1:1 volume of OMM containing no additional supplementation. Aggregates 
were transferred on culture day 18 to new 100 mm dishes in OMM containing no 
additional supplementation and maintained at 37C with weekly medium changes. 
Aggregates may be maintained in this manner for >150 days [19].  
 For studies with SHH pathway agonist Purmorphamine (PUR), aggregates 
were transferred to 100 mm plates on day 11-12 of culture and grown in OMM 
containing 1% Matrigel and CH (3 µM) (designated “CH” condition) or with OMM 
containing CH (3 uM) plus PUR (1 µM, except as specified) (designated 
“CH+PUR” condition) for four subsequent days of culture. On culture day 15, 
medium was aspirated completely and fresh OMM containing Matrigel and CH or 
CH+PUR was added to the plates with a 1:1 volume of OMM containing no 
additional supplementation. On day 18, aggregates were transferred as per the 
conventional protocol into OMM containing no additional small molecule 
treatments.  
  
Quantitative PCR   
 For qRT-PCR experiments, total RNA isolation from whole aggregates or 
sorted cell populations greater than 500,000 cells was performed using the 
RNeasy Plus Mini Kit (Qiagen, cat. no. 74134). Dissociated and sorted cell 
populations less than 500,000 cells underwent RNA isolation using the RNeasy 
Micro Kit (Qiagen, cat. no. 74004) suitable for small cell populations. cDNA was 
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generated using the Omniscript RT Kit (Qiagen, cat. no. 205111). For qRT-PCR, 
PowerUp SYBR Green Master Mix was utilized. Samples were run in technical 
triplicate, with L27 used as a reference gene for normalization. qRT-PCR 
experiments were run on a Bio-Rad CFX96 Touch platform, and Bio-Rad CFX96 




 For immunohistochemical analysis, aggregates were collected and fixed in 
4% paraformaldehyde for 30 minutes (if collected at a timepoint ≤day 40) or 1 
hour (if collected at a timepoint >day 40) at room temperature on a rotating table. 
Aggregates derived from human reporter ESCs were protected from light while 
undergoing fixation to avoid quenching of fluorescent signal. After fixation, 
aggregates were washed three times in 1X phosphate buffered saline (PBS; 
Gibco, cat. no. 10010049). Fixed aggregates were treated with 15% and 30% 
sucrose solutions for one hour each in serial, and then embedded in tissue 
freezing medium (Fisher Scientific, cat. no. 15-183-13), frozen at -20C for 30 
minutes to 1 hour, and stored at -30C until sectioning. Cryoblocks were sectioned 
into 12-15 µm sections using a Leica CM1850 Cryostat microtome. Each slide 
prepared for immunohistochemistry typically contained 5-10 cryosections 
representative of 5-10 aggregates embedded together (for samples collected 
≤day 30) or 3-4 aggregates embedded together (for samples collected ≥day 30).  
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Gene Primer set 
L27 Forward: CGTGAAGAACATTGATGATGGC 
Reverse: GCGATCTTCTTCTTGCCCAT 
PAX2 Forward: TCAAGTCGAGTCTATCTGCATCC 
Reverse: CATGTCACGACCAGTCACAAC 
KI67 Forward: CTGACCCTGATGAGAGTGAGGG 
Reverse: TCTCCCCTTTTGAGAGGCGT 
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 For fluorescent antibody staining, cryosections were blocked for 1 hour in 
PBS solution containing 0.1% Triton X-100 (Sigma-Aldrich, cat. no. 93443) and 
10% normal goat serum (Vector Laboratories, cat. no. S-1000). Primary and 
secondary antibody incubation occurred in PBS solution containing 0.1% Triton 
X-100 and 3% goat serum. Following blocking, cryosections were incubated in 
primary antibody solution for 1 hour at room temperature, or at 4C overnight (see 
Table 4 for list of primary antibodies used). Slides were then washed in PBS 
three times, 10 minutes per wash on an agitator at room temperature, covered to 
protect from light. Cryosections were then incubated with secondary antibody 
solution containing Alexa fluor-conjugated secondary antibodies for 1 hour at 
room temperature. Slides then underwent three 10-minute washes in PBS at 
room temperature, protected from light. Cryosections were fixed with Prolong 
Gold Antifade Reagent with DAPI (Fisher Scientific, cat. no. P-36931) for nuclear 
staining.  
 Imaging was performed using a Nikon TE2000 or Leica DMi8 inverted 
fluorescent light microscope. For Leica imaging, images were taken in Z-stacks 
and subjected to 3D deconvolution and projection.  
 
Fluorescence-activated cell sorting 
 Fluorescence-activated cell sorting (FACS) was used to assess PAX2-2A-
nGFP+ expression in control and treated PAX2 reporter human ESC-derived 
aggregates, and to isolate the GFP+ cell population for downstream analysis. For 
sorting, a desired number of aggregates were collected and pooled in one well of  
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Table 4: Primary antibodies 
 
  
Name Vendor Cat. no. Host Dilution 
PAX2 Abnova H00005076-M01 Mouse 1:100 
PAX8 Abcam AB97477 Rabbit 1:100 
SOX2 BD Pharmingen 561469 Mouse 1:100 
SOX10 eBioscience 14-5923-82 (20B7) Mouse 1:50 
FBXO2 Santa Cruz sc-398111 Mouse 1:25-1:50 
KI67 BD Pharmingen 550609 Mouse 1:100 
GFP Thermo Fisher A-11120 Mouse 1:100 
MYO7A Proteus 256790 Rabbit 1:100 
DLX3 Santa Cruz sc-514094 Mouse 1:100 
OTX2 R&D Systems AF1979 Goat 1:20 
NEUROD1 R&D Systems AF2746-SP Goat 1:50   
LMOD3 Proteintech 14948-1-AP Rabbit 1:50 
TUJ1 Abcam AB78717 Rabbit 1:100 
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a 24-well Nunclon Sphera Dish (Thermo Scientific, cat. no. 12-566-433) and 
washed three times with DPBS. Dissociation solution was prepared, consisting of 
DPBS containing 0.5X Accumax (Innovative Cell Technologies, cat. no. AM105), 
1X TrpLE Select (Fisher Scientific, cat. no. 50-591-353), and 0.5 mM EDTA. 1 
mL of dissociation solution was added to the aggregates. The 24-well plate was 
then placed at 37C. Aggregates were gently triturated by pipetting with P1000 
and P200 pipets (set to maximum volume) every 15 minutes for 1 hour, and 
imaged at the 30-minute and 60-minute mark to assess dissociation. Imaging 
was performed using a Nikon TE2000 inverted microscope. Dissociated cells 
were then run through a Falcon 100 µm mesh cell strainer (Fisher Scientific, cat. 
no. 08-771-19) and 40 µm mesh cell strainer (Fisher Scientific, cat. no. 07-201-
430) in succession. Dissociation to a single cell solution was confirmed by 
imaging. Viability was then assessed by staining with Trypan Blue (Thermo 
Fisher Scientific, cat. no. 15250061). A 1:1 volume of Trypan Blue and cell 
solution were combined in a 1.5 mL microcentrifuge tube, and 10 uL of the 
combined solution was loaded to each side of an Invitrogen Countess Cell 
Counting Chamber Slide (Fisher Scientific, cat. no. C10228). Cell count and 
viability were determined using a Countess II Automated Cell Counter (Thermo 
Fisher Scientific).  
 Dissociated cells were then spun down in a tabletop centrifuge for 3 
minutes at 200 g and re-suspended in 1 mL FACS wash. FACS wash consisted 
of DBPS with 1% BSA (Sigma, cat. no. A1470-10G) and 1 mM EDTA. The 
dissociated cell volume was then run through a Falcon 5 mL round bottom test 
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tube with cell strainer cap (Corning, cat. no. 352235) with an additional 1 mL of 
FACS wash in order to remove cell clumps. 25 uL of propidium iodide (Thermo 
Fisher Scientific, cat. no. P3566) diluted in PBS was added directly to the cells 
prior to sorting for dead cell exclusion.  
 Cells were sorted on a BD FACSAria SORP (BD Biosciences) at the 
Indiana University School of Medicine flow cytometry core. Aggregates derived 
from WA25 human ESCs lacking a fluorescent reporter cassette were 
dissociated in parallel with PAX2-2A-nGFP aggregates and used as negative 
fluorescence controls for FACS. With respect to gating strategy, forward scatter 
height versus forward scatter area was used to identify single cells and exclude 
doublets and cell clumps. Forward scatter area versus side scatter area was 
used to identify the cell population and exclude debris. Finally, propidium iodide  
was assessed to eliminate dead cells, and plotted against FITC to identify the live 
GFP+ cell population. Cells were sorted into DPBS containing 1% BSA and 
placed on ice until processing.  
 Generation of dot plots from FACS experiments and further analysis of 
quantitative data from FACS was performed using FlowJo flow cytometry 
analysis software (https://www.flowjo.com).  
  
Single-cell RNA-sequencing  
 For scRNA-seq studies, PAX2-2A-nGFP human ESCs were subjected to 
the inner ear differentiation protocol [19], subjected to either treatment with CH 
alone or dual CH+PUR treatment during culture day 11-18, and collected on 
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culture day 20. WA25 ESC-derived aggregates were cultured in parallel with the 
reporter aggregates, received the same treatments, and were collected at the 
same timepoint to serve as negative controls for FACS. Aggregates were 
dissociated for FACS as described in the previous section. For each scRNA-seq 
population, typically 30-50 aggregates per condition were collected and pooled 
into a single well of a 24-well plate, as described for FACS; triplicate wells were 
prepared for sorting (90-150 aggregates total to yield a single population for 
scRNA-seq). Cells were sorted to isolate the PAX2-2A-nGFP+ cell population, 
and brought to the Center for Medical Genomics at Indiana University School of 
Medicine for subsequent processing. 
 scRNA-seq experiments were conducted using the Chromium single cell 
3’ system (10X Genomics, Inc) and the NextSeq500 sequencer (Illumina, Inc). 
The single cell suspension obtained via FACS was first counted on the Countess 
II Automated Cell Counter  to determine cell number, cell viability, and cell size. If 
the assessed viability was higher than 85%, the appropriate number of cells was 
loaded onto a multiple-channel micro-fluidics chip compatible with the Chromium 
Single Cell Instrument (10X Genomics) with a targeted recovery of 10,000 cells. 
The version 2 single cell reagent kit (10X Genomics) was used, including gel 
beads containing barcoded oligonucleotides for tracing transcripts to their cell of 
origin, and reagents for reverse transcriptase. After individual cells were captured 
into oil droplets containing the barcoded gel beads, cells underwent lysis and 
cDNA was synthesized and amplified. cDNA was subsequently used to prepare a 
library for sequencing on the Illumina Nextseq500. A custom program was 
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utilized, wherein 26 base pairs of cell barcode and UMI sequence and 98 base 
pairs were generated.  
 To process raw sequence data, CellRanger 2.1.0 software 
(http://support.10xgenomics.com/) was used. Briefly, bcl2fastq  
(https://support.illumina.com/) was utilized in CellRanger to demultiplex raw base 
sequence calls generated from the sequencer into sample-specific FASTQ files. 
RNAseq aligner STAR was then used to align the FASTQ files to the human 
reference genome (GrCH38). Gene expression levels were quantified for each 
cell based on reads of individual unique molecular indices (UMIs); replicates of 
the same transcript shared the same UMI. Filtered gene-cell barcode matrices 
were generated by CellRanger for further analysis. The Seurat package in R 
(https://satijalab.org/seurat) was used for subsequent analysis, including 
unsupervised clustering and the integration of multiple datasets for comparative 
analysis. Here, datasets generated from CH and CH+PUR treated populations 
were integrated for comparative analysis. For day 20 analysis, each condition 
was performed in triplicate. For time course analysis comparing day 15 and day 
20 CH+PUR treated populations, a single day 15 CH+PUR scRNA-seq dataset 
was generated. 
 Additional plots were generated using Loupe Cell Browser software (10X 
Genomics). Loupe software is capable of interrogating gene expression targets in 
single populations, but cannot perform comparative analysis. Loupe generated 
plots are indicative of single datasets that have not undergone integrated 
normalization.  
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Statistical analysis   
 Statistics were conducted using Prism 7 Software 
(https://www.graphpad.com/scientific-software/prism/). For comparison of two 
groups, student’s t-test was applied. One-way ANOVA was applied for 
comparisons of more than two groups, with Dunnett’s multiple comparison test 
applied as a post hoc test. Significance was determined as p<0.05.  
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CHAPTER THREE: RESULTS 
Validation of inner ear organoid differentiation  
 I first sought to validate inner ear organoid generation using human WA25 
ESCs (Figure 9), as the formation of stem cell aggregates in 3D culture and 
subsequent differentiation of inner ear tissue serves as the foundation for this 
study. Morphological hallmarks of inner ear organoid development were 
observed as described in [19], including initial embryoid body formation (Figure 
9a), a thickening and ruffling of the outer epithelium by day 12 (Figure 9e), and 
the appearance of presumptive “otic pits” by culture day 15 (Figure 9f). Inner ear 
organoids were observed in late stage culture as either embedded (Figure 9h) or 
protruding (Figure 9i) spherical structures visible on the surface of the 
aggregates.  
 Protein expression analysis coincided with previous observations that otic 
placode and vesicle induction occurs in human stem cell-derived aggregates 
between days 12-18 [19], with co-expression of transcription factors PAX8 and 
SOX2 indicative of an early otic progenitor phenotype, observed by day 18 
(Figure 10a-c). Late stage immunohistochemical analysis validated the 
development of cells co-expressing hair cell marker MYO7A and SOX2 by 
culture day 60 (Figure 10d-f), indicative of a derived hair cell population. A 
SOX2+/MYO7A- cell population was also observed co-localizing with the derived 
hair cells, indicative of a supporting cell-like phenotype.  
 Taken together, 3D stem cell aggregates subjected to the inner ear 
differentiation protocol produced otic vesicles at early stages of culture, and were 
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Figure 9: Morphological progression observed in inner ear organoid culture.  
 
Stem cells were aggregated and treated with a series of small molecules during 
the first 8 days of culture to guide epithelium formation (a-d). A ruffled outer 
epithelium was visible by day 12 (e). Early otic vesicles pinch off from the surface 
of day 15 (f) aggregates and internalize by day 20 (g). Embedded (h) and 
protruding (i) organoids (arrowheads) may be observed in later stage cultures. 







Figure 10: Immunohistochemistry of early and late stage inner ear organoids 
confirms expression of markers of otic development.  
(a) Merged expression of early otic markers PAX8 and SOX2 in day 18 inner ear 
aggregates. Panels (b,c) illustrate Individual expression of SOX2 (b) and PAX8 
(c). (d) Expression of SOX2 and hair cell marker MYO7A in a late stage inner ear 
organoid. MYO7A/SOX2 co-expression is indicative of a hair cell phenotype. 
Some SOX2+ cells lack expression of MYO7A, indicative of a non-sensory 
supporting cell-like phenotype. Dashed box indicates area seen in (e). (f) 




capable of producing hair cell-like cells in long-term culture. This model appeared  
reproducible and suitable for the planned investigation. The majority of emphasis 
for the subsequent study will be placed on timepoints surrounding the induction 
of the derived otic vesicle (day 12-30) prior to the formation of hair cells, which 
are typically first observed in culture between day 40 to day 60 [19].  
      
PAX2-2A-nGFP reporter line allows for monitoring the development of 
derived otic progenitors  
 In order to assess the patterning phenotype of human ESC-derived otic 
vesicle stage aggregates, I wanted a tool to track and isolate this developing 
population in live cultures. This spurred an investigation into possible candidate 
markers to employ as an otic reporter. Paired box 2 (PAX2) is a transcription 
factor that is highly expressed in the developing mammalian inner ear [82-84]. 
Pax2 knockout mice exhibit disrupted cochlear development, with rudimentary 
cochlea formation but arrested cochlear growth observed during early stage 
development [84]. PAX2 mutations in humans have been associated with renal-
coloboma syndrome, a condition that impacts kidney and optic development. 
Sensorineural hearing loss has also been reported in patients with this mutation 
[85, 86].  
 PAX2 has previously been shown to be expressed in early stage human 
inner ear organoids, localizing in derived otic vesicle regions [19],. PAX2 protein 
expression has additionally been observed in organoids cultured for >60 days. 
Given the inner ear-specific expression of PAX2 previously reported in vivo [84, 
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87], and corroborated in our human inner ear organoid model, PAX2 appeared to 
be an excellent marker to validate the formation of early otic progenitors in 
culture, track the induction of this cell population in live aggregates, and isolate 
this population for downstream analysis. Therefore, we chose to employ a 
reporter line targeting PAX2 that was generated using CRISPR/CAS9 genome 
editing in WA25 human ESCs. This reporter line contained a 2A-nGFP sequence 
targeted to the PAX2 stop codon. Inclusion of a 2A linker sequence allows for bi-
cistronic expression from a single mRNA [88], meaning that GFP expression is 
driven by native PAX2 expression, but results in separate translation of PAX2 
and GFP, rather than the generation of a PAX2-GFP fusion protein. The GFP 
cassette additionally contained a nuclear localization signal, meaning the reporter 
line expresses GFP localized to the nucleus (nGFP). 
 PAX2-2A-nGFP reporter human ESCs were cultured according to our 
inner ear differentiation protocol [19] and monitored for the induction of GFP 
expression using fluorescent imaging of live cultures. The earliest instance of 
PAX2-2A-nGFP expression was observed on culture day 12 (Figure 11), with 
expansion of the PAX2-2A-nGFP+ cell population observed over the next several 
days in the protruding presumptive “otic pit” regions of the derived aggregates, 
leading to the formation of easily identifiable GFP+ vesicles.  
 Immunohistochemical analysis revealed that GFP expression overlapped 




Figure 11: Live imaging of PAX2-2A-nGFP aggregates.  
DIC and FITC imaging show structural morphology and induction of GFP+ cell 
population in PAX2-2A-nGFP human ESC derived aggregates. Dashed boxes 
indicate area in higher magnification shown in the lower set of panels. The 
earliest induction of GFP was observed in the aggregate outer epithelium on 
culture day 12, with expansion of the signal observed over time. Scale bars = 100 
µm. 
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Figure 12: PAX2 and GFP expression overlaps completely in PAX2-2A-nGFP 
aggregates.  
All time-points assessed exhibit overlap of PAX2 and GFP expression. PAX2 and 
GFP expression is low at culture day 12 (a) but expands in the outer epithelium 
of aggregates by culture day 15 (b) and 18 (c). (d-f) illustrate PAX2+/GFP+ otic 




                
 
Figure 13: Expression of otic markers supports otic identity of PAX2-2A-nGFP+ 
cell population.  
Immunohistochemical analysis of early stage otic markers PAX8 (a), SOX2 and 
ECAD (b) show localization with GFP in vesicle-like structures in day 18 
aggregates. Panels c-d illustrate co-localization or co-expression of PAX2-2A-
nGFP with SOX10 (c) and FBXO2 (d) in day 30 aggregates. (e) GFP localizes to 
vesicles with MYO7A+ putative hair cells in day 70 cultures. (f) PAX2 and GFP 
overlap is also observed in late stage cultures. Scale bars = 75 µm (a), 500 µm 
(b), 100 µm (c-f) 
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surveyed from day 12 to day 30 (Figure 12). Evaluation of additional early otic 
markers at culture day 18, including PAX8, SOX2 and E-cadherin (ECAD) 
(Figure 13a-b) showed co-expression with PAX2-2A-nGFP. Expression of otic 
markers SOX10 and FBXO2 (Figure 13c-d) showed either co-localization or co-
expression within PAX2-2A-nGFP+ vesicles, further supporting the otic identity of 
this GFP+ cell population. Late stage immunohistochemical analysis showed 
localization of PAX2-2A-nGFP to vesicles containing cells expressing hair cell 
marker MYO7A (Figure 13e). Additionally, late stage analysis showed that PAX2 
expression overlapped with expression of GFP (Figure 13f). 
 Having demonstrated the validity of this otic progenitor reporter line, these 
cells will serve as a tool to evaluate SHH pathway modulation in inner ear 
organoid culture.  
  
SHH pathway modulation in early stage inner ear organoids 
 SHH has been shown to be indispensable for proper cochlear 
morphogenesis [29, 31]. SHH loss-of-function studies revealed disrupted 
morphogenesis of both vestibular and auditory inner ear structures, a phenotype 
attributed to aberrant expression of dorsal genes and a lack of ventral gene 
expression in the developing otic vesicle. A study in which the SHH downstream 
effector SMO was conditionally inactivated in the mouse otic epithelium revealed 
that vestibular organ development was maintained following loss of SHH 
pathway activation in the inner ear; however, the cochlea failed to form in these 
embryos [31]. This was attributed to a loss of expression of PAX2 and OTX2 in 
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the ventral otic vesicle, while wild-type expression of dorsal-specific marker DLX5 
was maintained [31]. I hypothesize that activation of SHH signaling in early stage 
inner ear organoid culture will promote expression of ventral otic genes within the 
derived cell population. 
 To induce SHH pathway activation in the inner ear organoid model, 
Purmorphamine (PUR), a well-established small molecule agonist for SHH 
pathway effector Smoothened (SMO) [81, 89, 90], was selected. Aggregates 
were initially subjected to treatment with 1 µM PUR at day 11-12 of culture and 
maintained in medium containing PUR for an additional 6 days. During this time 
period, aggregates subjected to our previously published protocol are treated 
with WNT pathway agonist CHIR99021 (CH) to guide otic vesicle induction [19]. 
Morphological hallmarks associated with otic vesicle induction in inner ear 
organoids were not observed in PUR-treated aggregates, including the ruffling of 
the outer epithelium characteristic of presumptive otic pit formation during early 
stage culture (Figure 14). Instead, a condensed morphology with a darkened 
inner core was observed in these aggregates. Additionally, aggregates treated 
with PUR appeared not to express PAX2-2A-nGFP when assessed by live 
fluorescent imaging (Figure 14a). Pilot qRT-PCR analysis confirmed decreased 
expression of PAX2 in aggregates receiving PUR only compared to those treated 
with CH at this timepoint (Figure 14b). Taken together, these data indicated that 
treatment with PUR alone appeared insufficient to guide the formation of otic 
vesicles. For that reason, in subsequent PUR experiments, aggregates received  
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Figure 14: Purmorphamine treatment alone fails to induce presumptive otic 
vesicles.  
(a) PAX2-2A-nGFP human ESC-derived aggregates treated with Wnt agonist CH 
from culture day 11-18 exhibit PAX2-2A-nGFP+ vesicle-like structures by culture 
day 18. Aggregates treated with PUR alone during this time period do not exhibit 
PAX2-2A-nGFP+ vesicles. Scale bars = 100 µm (b) Pilot qRT-PCR analysis of 
PAX2 expression in day 18 PAX2-2A-nGFP ESC-derived whole aggregates 





Figure 15: Size phenotype observed in CH+PUR treated aggregates.  
(a-b) DIC images of day 18 WA25 aggregates receiving CHIR treatment alone 
(a) or CHIR + Purmorphamine (b). (c) Size comparison data between CH and 
CH+Pur aggregates showing average area. **** indicates indicates significance, 
p-value >0.0001 (n= 18 aggregates per condition, 3 independent experiments). 
Error bars indicate SD. (d-e) PAX2 and KI67 expression in CH (d) and CH+PUR 
(e) aggregates. (f) Pilot qRT-PCR analysis indicating relative normalized 
expression of KI67 in CH and CH+PUR whole aggregates. Scale bars = 100 µm.  
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dual CH and PUR treatment (indicated as CH+PUR) to ensure otic vesicle 
induction.   
 A size phenotype was observed following dual CH+PUR treatment 
beginning on day 11-12 of culture and spanning the period of otic vesicle 
formation (up to day 18 of culture). CH+PUR treated aggregates grew 
significantly larger than control aggregates treated with CH alone (Figure 15a-b). 
Immunohistochemical analysis confirmed the appearance of PAX2+ vesicles in 
CH+PUR treated aggregates, shown on day 18 (Figure 15e). Expression of 
proliferation marker KI67 (KI67) appeared more abundant in CH+PUR treated 
aggregates; a similar trend was observed in preliminary qRT-PCR analysis 
(Figure 15f). The size phenotype may be reflective of the mitogenic role of the 
SHH signaling pathway [71]. 
 Dose response analysis was performed in order to assess the optimal 
concentration of PUR treatment (Figure 16). PAX2-2A-nGFP derived aggregates 
were treated with a consistent concentration of CHIR (3 µM, as reported in [19]), 
and increasing concentrations of PUR, ranging from 0.5-4 µM. GFP expression 
was observed in live cultures during the period of otic vesicle induction (day 11-
18). Aggregates treated with 0.5-2 µM PUR exhibited relatively typical 
morphology and patterns of PAX2-2A-nGFP expression (Figure 16a). However, a 
sharp decrease in culture quality was observed in aggregates treated with 4 µM 
PUR, with cellular debris noted surrounding the aggregates during the treatment 
period. Additionally, PAX2 expression in aggregates treated with 4 µM PUR 
appeared diffuse and dim, with little evidence of PAX2+ vesicles observed in live  
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Figure 16: Purmorphamine dose response. 
 
(a) DIC/FITC imaging of PAX2-2A-nGFP human ESC-derived aggregates. 
Dashed boxes indicate area of magnification seen in lower panels. Scale bars = 
100 µm (b) Average aggregate area per treatment, n= 18 aggregates per 
condition from 3 independent experiments. * indicates significance, p-value = 




cultures (Figure 16a). With respect to aggregate size, aggregates receiving 1 µM 
PUR were significantly larger in area than those receiving CH alone (p=0.0366, 
n=18 aggregates, 3 independent experiments) (Figure 16b), supporting previous 
results obtained comparing size in CH treated and CH+PUR (1 µM) treated 
WA25 human ESC-derived aggregates (Figure 14c). Concentrations of 0.5, 2, 
and 4 µM PUR did not exhibit a significant size difference compared to 
aggregates treated with CH alone  (Figure 16b). A concentration of 1 µM PUR 
was ultimately selected for subsequent analysis.  
 
Isolation and FACS analysis of PAX2-2A-nGFP+ derived cell populations 
 One challenge of the inner ear organoid model is the heterogeneous 
nature of the stem cell derived aggregates; non-otic cell types routinely emerge 
alongside the otic cell population. In order to accurately assess the gene 
expression phenotype of the otic population, it was necessary to optimize a 
strategy for dissociation and FACS of PAX2-2A-nGFP human ESC-derived 
aggregates to isolate the PAX2-2A-nGFP+ population (Figure 17). There have 
been no previously published methods for the dissociation of stem cell-derived 
inner ear organoids. Extensive troubleshooting ultimately led to the modification 
of a method from Herget and colleagues [91], who dissociated chicken vestibular 
sensory epithelia for flow cytometry using an enzymatic cocktail consisting of 
AccuMax Cell Dissociation solution (Cell Technologies, Inc.), trypsin, and EDTA. 
Herget et al found that incubation of dissected vestibular sensory epithelia in 
enzyme solution for 7 minutes at 37C, with gentle mechanical dissociation after 3  
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Figure 17: Fluorescence-activated cell sorting of PAX2-2A-nGFP aggregates 
allows for isolation of GFP+ cell population.  
(a) Schematic describing strategy for analysis of PAX2-2A-nGFP aggregates. (b) 
DIC and FITC imaging shows Day 20 PAX2-2A-nGFP aggregate prior to 
dissociation (left panels), post-dissociation (middle) and post-sort (right). Scale 
bars = 100 µm (c) Representative dot plots illustrating gating strategy for WA25 
negative fluorescent control cells (top panels) and PAX2-2A-nGFP sorted cell 
population (bottom panels). FITC axis represents GFP. Propidium iodide stain, 
indicated by PerCP-Cy5-5-A axis, was included for dead cell exclusion.    
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minutes of incubation, led to efficient dissociation and generation of a single-cell 
suspension [91]. 
 The aggregates subjected to the human ESC inner ear differentiation 
protocol required a substantially longer incubation time for dissociation. For pilot 
dissociation experiments, aggregates collected were collected day 18-25 and 
placed in dissociation solution consisting of 0.5X AccuMax, 1X TrypLE, and 0.5 
mM EDTA. Time course analysis was performed to evaluate the optimal length of 
time for incubation, using viability as assessed by trypan blue staining and 
formation of a single-cell solution as a measure of efficacy (data not shown). The 
optimal dissociation conditions for FACS of human stem cell-derived inner ear 
aggregates comprised a one-hour static incubation at 37C with periodic gentle 
mechanical trituration. This method maintained adequate cell viability as 
assessed by propidium iodide staining during sorting (Figure 17c).  
 FACS was performed on day 20 PAX2-2A-nGFP human ESC-derived 
aggregates treated with either CH or CH+PUR during otic vesicle induction 
(Figure 18a), with WA25 timepoint-matched aggregates used as a GFP negative 
control. Analysis at day 20 revealed a trend toward an increased PAX2-2A-
nGFP+ population in the CH+PUR treated group compared to aggregates treated 
with CH alone (Figure 18b), although the difference was not statistically 
significant across three replicates.  
 Altogether, we established a method for dissociation and FACS of otic 
vesicle stage inner ear organoids and demonstrated the ability to isolate 
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Figure 18: Fluorescence activated cell sorting of CH and CH+PUR treated 
aggregates.  
Representative dot plots of PAX2-2A-nGFP FACS, indicating sorted cell 
populations from WA25 aggregates prepared as a negative control for GFP 
expression (a), aggregates receiving CH treatment alone (b), and aggregates 
receiving CH+PUR treatment (c). Percentage of PAX2-2A-nGFP expression 
indicated in upper left quartile. Panel (d) indicates the average percentage of 
GFP+ cells per condition, n=3 biological replicates per condition (indicative of 
aggregates from three independent cultures prepared for three individual FACS 







PAX2-2A-nGFP+ presumptive otic progenitors. This method will be further 
employed for subsequent transcriptomic analysis of CH and CH+PUR treated 
aggregates. 
  
Evaluation of control and treated cell populations via single-cell RNA-
sequencing 
 Having successfully isolated PAX2-2A-nGFP+ cells from early stage inner 
ear organoids, our next goal was to analyze the gene expression profile of sorted 
cell populations. Expression of dorsal and ventral inner ear patterning markers 
has not previously been evaluated within the inner ear organoid model. Single-
cell RNA-sequencing (scRNA-seq) was performed at day 20, a timepoint 
following otic vesicle induction, to determine whether a dorsalized phenotype is 
present in control treated (CH) aggregates, potentially underlying the vestibular 
bias in subsequent hair cell differentiation, and whether SHH pathway modulation 
may promote ventralization and lead to induction of cochlear cell types. 
 scRNA-seq platforms have evolved greatly in recent years, increasing in 
high-throughput capability [61]. For the scRNA-seq experiments described here, 
the 10X Chromium 3’ single-cell platform was utilized. PAX2-2A-nGFP derived 
aggregates were treated with either CH or CH+PUR from day 11 to day 18 and 
monitored for induction of PAX2-2A-nGFP. Aggregates were collected on day 20 
of culture and sorted to isolate the PAX2-2A-nGFP population. The GFP+ cells 
were then subjected to scRNA-seq. Each treatment group was replicated three 
times, for a total of six individual scRNA-seq datasets. Variation was observed 
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from sample to sample within each treatment group with respect to number of 
cells read, as well as with respect to the expression of certain individual markers. 
scRNA-seq analysis provides only a snapshot of cells at the time they were 
isolated, so some natural variation is to be expected. However, results presented 
here for specific genes of interest were consistent across replicates unless 
otherwise specified. The following passages will detail processing and quality 
control analysis of one representative sample set.  
 To process each cell population following scRNA-seq, quality control 
analysis was performed using Seurat [92, 93]. Cell filtering was applied based on 
the number of genes expressed per cell and the number of mitochondrial genes 
present. High mitochondrial gene content may be indicative of poor cell quality 
[94]. For the first CH control population processed, cells with unique gene counts 
greater than 5,500 and less than 1,000 were filtered out, along with cells that 
displayed greater than 6% mitochondrial gene expression (Figure 19). These 
filtering metrics eliminated 0.014% of the cell population from subsequent 
analysis, reducing the data set from 6967 cells to 6866 cells. The same approach 
was used to filter the first CH+PUR dataset, excluding 0.011% of the total cell 
population, thereby reducing the initial sample size of 8798 cells to 8693 cells 
after filtering. For all replicate samples, consistent quality control metrics for 
filtering and processing were applied.  
 Data was then normalized via a global-scaling normalization method in 
Seurat; gene expression measurements for each cell were normalized by the   
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Figure 19: Quality control analysis of CH and CH+PUR treated PAX2-2A-nGFP+ 
‘cell populations.  
(a-b) Dot plots indicating the number of genes expressed, number of UMI counts, 
and percentage of mitochondrial genes expressed in the evaluated cell 
populations for representative CH (a) and CH+PUR (b) treated cell populations. 
(c-d) Plots illustrating the gene number density and percentage of mitochondrial 




         
Figure 20: Clustering of CH treated single-cell population.  
(a) Clustering analysis distinguished 14 individual clusters of differential gene 
expression (numbered 0-13) in the CH treated sorted cell population. (b) 
Heatmap illustrating differential gene expression among the 14 clusters. 
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Figure 21: Clustering of CH+PUR treated single-cell population. 
(a) Clustering analysis distinguished 16 individual clusters of differential gene 
expression (numbered 0-15) in the CH+PUR treated sorted cell population. (b) 





total expression, multiplied by a scaling factor of 10,000 and log-transformed. 
Highly variable genes were then identified for downstream analysis. For the CH 
dataset, 1609 variable genes were identified (Figure 20). Principle component 
analysis (PCA) was performed, and a graph-based clustering approach was 
applied to visualize the data. Non-linear dimensional reduction visualized via t-
distributed stochastic neighbor embedding (tSNE) revealed 14 clusters of 
differential gene expression within the CH dataset. 1668 variable genes and 16 
clusters were identified for the CH+PUR dataset (Figure 21) using the same 
clustering and visualization method.  
 
Evaluation of dorso-ventral patterning markers  
 The goal of this scRNA-seq analysis was to evaluate the patterning 
phenotype of early derived otic progenitors in control conditions (CH) and in cells 
additionally exposed to SHH pathway agonist PUR (CH+PUR) to determine 
whether control cells exhibit a more dorsalized phenotype, and whether SHH 
pathway modulation may increase expression of ventral otic markers. 
Comparative analysis of the two datasets was performed in order to evaluate 
differential expression of markers of interest between the two treatment groups. 
In particular for my analysis, focus was initially placed on markers of otic 
development, SHH pathway component expression, and dorsal and ventral otic 
vesicle patterning markers. Figure 4, featured in CHAPTER ONE: 
INTRODUCTION, lists key markers of otic induction, many of which were 
evaluated among the scRNA-seq datasets.  
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 For comparative analysis, CH and CH+PUR datasets were combined and 
filtered according to previous mentioned quality control metrics, including 
mitochondrial gene and total gene expression. Integrated analysis was then 
performed, in which the pooled datasets were clustered by PCA and visualized 
via tSNE (Figure 22). Fifteen clusters of differential gene expression were 
identified for the combined population. Genes of interest were individually 
evaluated and will be discussed further below. 
 
Otic marker expression observed in PAX2-2A-nGFP+ populations 
 We first assessed the expression of otic markers among the cell 
populations of both treatment groups. PAX2 is expressed in otic progenitors of 
the developing inner ear, but has also been observed in other areas during 
development, including the central nervous system and kidney [83, 95]. 
Therefore, we wanted to confirm the presence of an otic population within the 
isolated PAX2-2A-nGFP+ cells. Coinciding with the observations from our 
immunohistochemical analysis of PAX2-2A-nGFP aggregates, both CH and 
CH+PUR sorted cell populations exhibited expression of otic markers PAX8, 
SOX2, SOX10, and FBXO2. 
 Figure 23 shows localization of these markers within both the CH and 
CH+PUR populations (Figure 23a-d). Between the two treatment groups, the 
percentages of cells expressing PAX8, SOX10, and FBXO2 were not significantly 
different (Figure 23e), though variation from marker to marker was observed. 
Only a small percentage of cells, 2.09±0.46% (±sem, n= 3 independent datasets  
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Figure 22: Integrated analysis of CH and CH+PUR datasets.  
For comparative analysis, CH and CH+PUR datasets are pooled. Panel (a) 
depicts overlay of the two populations, with CH cells indicated in green and 
CH+PUR cells indicated in blue. Combined datasets were then subjected to PCA 
and projected via tSNE for differential clustering (b). For the integrated dataset, 
15 individual clusters were observed (labeled 0-14). 
78 
       
Figure 23: Otic marker expression in single-cell datasets. 
Both CH and CH+PUR treated populations were observed to express markers of 
early otic development include PAX8 (a), SOX2 (b) SOX10 (c), and FBXO2 (d). 
Expression of these markers within the sorted PAX2-2A-nGFP+ populations 
supports an early otic progenitor phenotype within each treatment group. Panel 
(e) indicates the average percentage of cells expressing these markers across 
(3) replicate datasets per condition. Error bars indicate sem. * indicates 
significance, p=0.046. 
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per treatment group) in the CH treatment group and 2.64±0.25% in the CH+PUR 
treatment group, expressed otic placode marker PAX8 (Figure 23e). SOX10 was 
expressed in 7.57±0.73% of CH-treated cells and 13.74±3.59% of CH+PUR 
treated cells, whereas FBXO2 expression was observed in 24.14±5.90% of CH 
treated cells and 18.76±1.75% of CH+PUR treated cells. Notably, the percentage 
of cells expressing otic progenitor marker SOX2 was significantly different 
between the two treatment groups; SOX2 expression was observed in 
29.47±9.53% of CH treated cells, and 47.75±3.14% of CH+PUR treated cells. It 
is important to note that SOX2 and FBXO2 may also be expressed in neural cell 
types [96-98].  
 Overall, single-cell analysis confirmed expression of mRNA for otic 
markers within both treatment groups, coinciding with our previous observations 
of protein expression of these markers in PAX2-2A-nGFP derived aggregates 
subjected to our inner ear organoid differentiation protocol (Figure 13). Of the otic 
markers evaluated, only SOX2 exhibited significant enrichment in the CH+PUR 
treated population. 
   
Expression of SHH pathway components    
 We next sought to assess the expression of SHH pathway components 
within the CH and CH+PUR cell populations, to evaluate whether SHH signaling 
activation was occurring in the CH+PUR treated cultures. Patched1 (PTCH1) is 
the cell surface receptor for SHH, and is itself regulated by the SHH signaling 
pathway [99]. Figure 24 illustrates the localization of PTCH1 expressing cells 
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amongst the CH and CH+PUR treated populations (Figure 24a). The relative 
normalized expression of PTCH1 also appeared increased in the CH+PUR 
treated population, as did the number of cells expressing PTCH1 (Figure 24b). 
Quantitative analysis across three replicates revealed the percentage of cells 
expressing PTCH1 was significantly larger in the CH+PUR treated population 
compared to the population treated with CH alone (Figure 24d).  
 Evaluation of GLI1, a downstream SHH pathway transcription factor also 
regulated by SHH signaling [100], demonstrated expression in the representative 
CH+PUR treated population, but no expression in the CH treated population 
illustrated in Figure 24 (Figure 24c). However, GLI1 expression was observed in 
the CH treated populations of the two additional replicate datasets, so the lack of 
GLI1 expression in this CH dataset appeared to be sample-specific, and may be 
an artifact of library preparation and/or filtering. Across the three replicate 
datasets per treatment, GLI1 was expressed in 0.11±0.06% (±sem, n=3 
replicates per condition) of CH treated cells, and 2.85±0.64% of CH+PUR treated 
cells. SHH pathway components SMO, GLI family zinc finger 2 (GLI2), and GLI 
family zinc finger 3 (GLI3), which are not directly regulated by SHH signaling, 
were shown to have comparable expression in both the CH and CH+PUR 
treatment groups (Figure 24d-f). The percentage of cells expressing each of 
these pathway components was not significantly different between the two 
treatment groups (Figure 24g). Overall, assessment of SHH pathway 
components appeared to indicate that GLI2, GLI3, and SMO were unaffected 
between the two treatment groups. However, SHH pathway-regulated PTCH1 did  
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Figure 24: SHH pathway component expression. 
(a) Comparative analysis revealed differential expression of SHH pathway 
component PTCH1. (b) Violin plots illustrating relative normalized expression of 
PTCH1 among the single-cell populations; each dot is representative of one cell. 
(c) Localization of GLI1 expression among both treatment groups. (d) Average 
percentages of PTCH1 and GLI1-expressing cells. n=3 replicate datasets per 
treatment group; error bars indicate sem, * indicates significance, p=0.0005. (e) 
Localization of other SHH pathway components whose expression is not 
dependent on SHH signaling, GLI2, GLI3, and SMO. (f) Violin plots illustrating 
relative normalized expression of GLI2, GLI3, and SMO. (g) Average 
percentages of GLI2, GLI3, SMO-expressing cells. n= 3 replicate datasets per 
treatment group, error bars indicate sem. 
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exhibit increased expression in the CH+PUR treated population, supporting SHH 
pathway activation following PUR treatment in inner ear organoid cultures.  
 
Ventral patterning marker analysis  
 Several previously validated markers of the ventral otic vesicle, including 
LFNG, OTX1, and OTX2 [29, 31, 101], were evaluated in the CH and CH+PUR 
datasets to determine whether CH+PUR treatment enhances expression of 
ventral genes. Figure 25 illustrates the localization of each marker among the CH 
and CH+PUR populations among one set of representative samples (Figure 
25a). Violin plots illustrate the relative normalized expression of each marker per 
treatment group (Figure 25b). Across three replicate datasets, a significantly 
higher percentage of cells expressing LFNG was observed in the CH+PUR 
treated population compared to those cells receiving CH alone, with 8.21±1.45% 
(±sem, n=3 replicates per condition) of CH+PUR treated cells expressed LFNG 
and 1.68±0.21% of CH treated cells expressing LFNG (Figure 25c). Additionally, 
a significantly higher percentage of CH+PUR treated cells expressed OTX1 
(6.08±2.00%), compared to 0.77±0.39% of CH treated cells (Figure 25c). 
However, expression of ventral marker OTX2 was seen in a higher percentage of 
cells in the CH-treated group compared to CH+PUR, with 1.46±0.18% of CH-
treated cells expressing OTX2, compared to 0.78±0.02% of CH+PUR treated 
cells, although the difference was not statistically significant across the triplicate 
datasets. Immunohistochemical analysis of OTX2 revealed the occurrence of 
both OTX2+ cells and GFP+/OTX2+ cells (Figure 26). The single-positive  
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Figure 25: Ventral patterning marker analysis. 
(a) Dot plots illustrating localization of ventral markers within each treatment 
group; datasets were normalized for comparative analysis. (b) Violin plots of 
candidate ventral genes LFNG, OTX1, and OTX2. Y-axis represents relative 
normalized expression. Each dot corresponds with a cell expressing the 
candidate gene. (c) Average percentage of cells expressing each marker; n= 3 
replicate datasets per treatment group, error bars indicate sem, ** indicates 





Figure 26: Immunohistochemical analysis of ventral marker OTX2 in CH and 
CH+PUR treated aggregates. 
 
Staining for OTX2 and GFP in cryosections of early stage aggregates reveal 
localization of OTX2 in GFP+ vesicles. OTX2+/GFP+ cells are observed in both 




population was likely excluded due to FACS isolating PAX2-2A-nGFP+ cells only, 
and may not be representative of the total OTX2+ cell population co-localizing 
with GFP+ vesicles. In vivo, PAX2 and OTX2 expression does not overlap 
completely [84]; therefore, the OTX2+/GFP- population in the derived aggregates 
may still be representative of otic progenitors exhibiting a ventral phenotype.  
 
Dorsal patterning marker analysis    
 Single-cell analysis was used to interrogate patterning markers of the 
dorsal otic vesicle, the region from which the vestibular organs arise. We first 
evaluated expression of distal-Less homeobox transcription factors DLX3, DLX5, 
and DLX6 (Figure 27), which are expressed in the dorsal otic vesicle [102]. Both 
DLX3 and DLX5 appeared to exhibit lower relative normalized expression in the 
CH+PUR treated group compared to cells treated with CH alone (Figure 27b). 
The percentage of cells expressing DLX5 was not significantly different between 
the two treatment groups, as was the case with DLX6 (Figure 27c). However, 
DLX3 was expressed in a significantly lower percentage of cells treated with 
CH+PUR compared to the CH treated population with expression observed in 
5.45±1.02% (±=sem, n=3 replicate datasets) of CH+PUR treated cells compared 
to 17.27±4.17% of cells treated with CH alone (Figure 27c). The results with 
DLX3 were supported by immunohistochemical analysis, wherein DLX3 
expression was observed co-localized in areas of GFP expression in CH treated 
aggregates, but not in CH+PUR treated aggregates (Figure 28).   
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Figure 27: Expression of dorsal markers DLX3, DLX5 and DLX6 in CH and 
CH+PUR treated populations. 
(a) Localization of dorsal markers DLX3, DLX5, and DLX6 within the CH and 
CH+PUR treated populations. Datasets have been normalized for comparative 
analysis. (b) Violin plots illustrating expression of DLX3, DLX5, and DLX6. Y-axis 
represents relative normalized expression. (c) Percentage of cells expressing 
DLX markers within the CH and CH+PUR datasets. Error bars indicate sem, * 




Figure 28: Immunohistochemical analysis of dorsal marker DLX3 in CH and 
CH+PUR treated aggregates. 
Cryosections from CH and CH+PUR treated aggregates stained for DLX3 and 
GFP revealed co-localization of DLX3 with GFP+ areas in CH but not CH+PUR 





 Both populations also exhibited expression of dorsal markers LMX1A and 
WNT2B (Figure 29a). However, a significantly lower percentage of cells treated 
with CH+PUR expressed WNT2B, with 2.22±0.64% of CH+PUR treated cells 
expressing WNT2B, compared to 6.69±0.76% of cells in the CH treated  
population (Figure 29b). Additionally, a significantly lower percentage of 
CH+PUR treated cells expressed LMX1A, with 0.74±0.31% of CH+PUR treated 
cells exhibition LMX1A expression, compared to 5.80 ±1.63% of cells in the 
population receiving CH alone (Figure 29b). Relative normalized expression also 
appeared lower in the CH+PUR treated group compared to the CH treated group 
for both markers (Figure 29c). 
 Overall, these findings indicate a significant reduction in the incidence of 
select dorsal markers among the CH+PUR treated population, although the 
phenotype does not appear consistent across all dorsal markers examined.  
 
Increased neural population observed in SHH pathway modulated cell 
population 
 During development, the cochleo-vestibular ganglion emerges from the 
antero-ventral region of the otic vesicle, initially observed as a population of cells 
expressing transcription factors NEUROG1 and NEUROD1 [103]. Interestingly, 
single-cell analysis revealed significantly higher expression of both neural factors 
among the CH+PUR treated population. Figure 30 illustrates the localization and 
relative normalized expression of NEUROD1 (Figure 30a) and NEUROG1 
(Figure 30b) among the CH and CH+PUR treated populations.  
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Figure 29: Evaluation of additional dorsal markers within the CH and CH+PUR 
sorted populations.   
(a) Localization of dorsal markers LMX1A and WNT2B within the CH and 
CH+PUR treated populations. Datasets have been normalized for comparative 
analysis. (b) Average percentage of cells expressing LMX1A and WNT2B within 
the CH and CH+PUR datasets. Error bars indicate sem, * indicates significance, 
p=0.0124 (LMX1A), p=0.0234 (WNT2B). (c) Violin plots illustrating expression of 





Figure 30: CH+PUR treated cultures exhibit an increased neural population. 
Localization and relative normalized expression of inner ear neuroprogenitor 
markers NEUROD1 (a) and NEUROG1 (b). (c) Average percentage of cells 
expressing NEUROD1 and NEUROG1 (n= 3 replicates per treatment). Error bars 
indicate sem, **** indicates significance, p<0.0001, *** indicates significance, 
p=0.008 (d-e) Expression patterns of inner ear neural markers HES6 (d) and ISL-
1 (e) in the CH and CH+PUR treated populations.   
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Among the CH+PUR population, 42.52±3.27% (±= sem, n= 3 replicate datasets 
per condition) of cells expressed NEUROD1 and 30.54±0.71% cells expressed 
NEUROD1, while the CH treatment group exhibited NEUROD1 expression in 
10.67±3.27% of cells, and NEUROG1 expression in 8.30±2.67% of cells (Figure 
30c).  
 In mice, Neurog1 expression precedes NeuroD expression in otic neural 
precursors, with Neurog1 observed at E9.0, and NeuroD induction observed by 
E9.5 [104]. Both the CH and CH+PUR cell populations exhibited a larger 
percentage of cells expressing NEUROD1 compared to NEUROG1. The CH and 
CH+PUR presumptive neural populations additionally contained cells expressing 
proneural markers HES6 (Figure 30d) and ISL-1 (Figure 30e). Cells exhibiting 
expression of these markers within the NEUROD1/NEUROG+ clusters mirror the 
phenotype of neuroblasts delaminating from the early otic vesicle [96, 105, 106]. 
 Immunohistochemical analysis confirmed NEUROD1 protein expression in 
both CH and CH+PUR treated aggregates (Figure 31). Figure 31 illustrates the 
co-localization of NEUROD1 within PAX2-2A-nGFP+ vesicles in both treatment 
groups. NEUROD1+/GFP+ cells were observed within the vesicles. Both 
treatment groups additionally exhibited NEUROD1+/GFP- cells both within and 
surrounding the vesicles.  
 The expanded neural population observed in the CH+PUR cell population 
spurred interrogation of additional neural markers among the CH and CH+PUR 
scRNA-seq datasets. We previously observed the emergence of cells co-
expressing neuronal markers TUBB3 (TUJ1) and POU4F1 between 20-30 days  
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Figure 31: Immunohistochemical analysis of inner ear neuroprogenitor marker 
NEUROD1 in CH and CH+PUR treated aggregates. 
Antibody staining for NEUROD1 confirms scRNA-seq observations of an 
increased NEUROD1 population in CH+PUR treated aggregates. A 
NEUROD1+/PAX2- population is also observed in both treatment conditions. 





Figure 32: Additional neural marker expression in CH and CH+PUR treated 
populations. 
Expression of neural markers TUBB3, POU4F1, and NEFL was observed in both 
CH and CH+PUR treated populations, with expanded expression of POU4F1 and 




of inner ear organoid culture [19]. Single-cell analysis revealed that this 
population is evident in both CH and CH+PUR treated PAX2-2A-nGFP+ cells 
(Figure 32). Figure 32 depicts individual populations from representative CH and 
CH+PUR datasets. These plots were generated using Loupe Cell Browser 
software, and represent datasets that have not been integrated for comparative  
analysis. As such, quantitative observations cannot be made from these plots. 
Additional comparative analysis may be performed in order to facilitate 
quantitative analysis. Nonetheless, Figure 32 illustrates expression of both 
TUBB3 and POU4F1 among the CH and CH+PUR datasets. TUBB3-expressing 
cells are interspersed throughout the CH treated population, while POU4F1 
exhibits highly restricted localization to a presumptive neural cluster. Within the 
CH+PUR treated population, TUBB3 is also exhibited across the population, 
while POU4F1 expression is robust and highly exhibited within the presumptive 
neural clusters. Additionally, expression of Neurofilament light chain (NEFL), a 
marker abundantly expressed in axons of the central nervous system (CNS) and 
peripheral nerves, appeared enriched in the CH+PUR treated population 
compared to cells treated with CH alone (Figure 32). Previously published 
immunohistochemical analysis revealed expression of NEFL in day 60-75 inner 
ear organoids [19]. This scRNA-seq analysis indicates the presence of this 
presumptive neural NEFL+ population in otic vesicle stage aggregates. 
 Due to the neuroprogenitor-like phenotype observed within the scRNA-seq 
datasets, we elected to examine the expression of markers indicative of 
vestibular ganglion or spiral ganglion development within the individual datasets.   
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Both the CH and CH+PUR populations exhibited expression of markers of 
vestibular ganglion development ONECUT1 and PCDH19 [107] (Figure 33). 
Within the CH treated population, ONECUT1+ cells appeared restricted to the 
NEUROD1/NEUROG1+ presumptive neural cluster, whereas expression of 
PCDH19 was observed both within and outside of this presumptive neural 
population. In the CH+PUR treated population, ONECUT1+ cells were observed 
among the presumptive neural population. Expression of PCDH19 was observed 
both within the presumptive neural population and elsewhere in the population as 
a whole (Figure 33). 
 Expression of SGN-associated markers SHOX2, INSM1, INSM2, and 
ST18 was additionally observed in both populations (Figure 34). In the CH 
treated population, expression appeared restricted to the presumptive neural 
clusters. In the CH+PUR population, robust expression of SHOX2 and INSM1 
was observed, along with expression of INSM2 and ST18 in the expanded 
presumptive neural regions. BDNF expression was also seen in both treatment 
groups; this factor has been shown to be a key element for the development of 
synaptic connections between SGNs and sensory cells of the cochlea [104, 108].  
 Expression of these markers could be indicative of SGN and VGN 
precursors arising within the presumptive neural populations of both treatment 
groups, with more widespread expression observed in the CH+PUR treated 
population. Taken together, these data support a neural phenotype in both CH 
and CH+PUR treated cell populations reminiscent of progenitors of the 




Figure 33: Markers of vestibular ganglion neuron development.  
scRNA-seq analysis revealed expression of markers of vestibular ganglion 
neuron development, ONECUT1 and PCDH19, in both the CH and CH+PUR 
populations. Scales indicate Log2 gene expression. 
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Figure 34: Markers of spiral ganglion neuron development. 
Both CH and CH+PUR treated populations contained cells expressing spiral 
ganglion neuron markers SHOX2, INSM1, INSM2, and ST18. BDNF, a factor 
necessary for the development of connections between SGNs and cochlear hair 
cells, is also expressed. Scales indicate Log2 gene expression. 
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Figure 35: Temporal analysis of CH+PUR treatment.  
scRNA-seq analysis of day 15 CH+PUR treated samples was performed for 
comparison with day 20 CH+PUR treated samples. Expansion of the NEUROD1 
population was observed, along with restriction of NEUROG1 expression from 
day 15 to day 20. MKI67 expression also appeared downregulated between the 




enriched in the population receiving CH+PUR during otic vesicle formation, 
indicating that SHH pathway modulation in early stage culture may bias 
differentiation toward a neuroprogenitor rather than an epithelial fate.  
 
Temporal gene expression changes in Purmorphamine treated cultures  
 Time course analysis was performed to track temporal expression of 
markers of inner ear development in response to SHH pathway modulation. 
PAX2-2A-nGFP aggregates were treated with CH+PUR on culture day 11 and 
collected on culture day 15. At this timepoint, PAX2-2A-nGFP+ cells are 
observed localized to presumptive otic pit regions extending from the surface of 
the aggregates (Figure 10). scRNA-seq was performed on sorted day 15 PAX2-
2A-nGFP+ cells for comparison to a day 20 CH+PUR treated dataset. 
Preliminary analysis revealed an expansion of the NEUROD1+ population from 
day 15 to day 20 (Figure 35). Conversely, more widespread and robust 
NEUROG1 expression was observed throughout the population on day 15, 
becoming somewhat more restricted by day 20. There was also an apparent 
reduction in expression of cell cycle marker MKI67 from day 15 to day 20, 
indicating a potential decrease in proliferation between these two timepoints 
(Figure 35). 
 
Late stage evaluation of Purmorphamine treatment    
 Preliminary late stage analysis was performed to assess the effects of 
dual CH+PUR treatment on late stage aggregates, with an emphasis on hair cell 
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differentiation, to evaluate if SHH pathway modulation impacts the derived hair 
cell population, in particular biasing differentiation toward a cochlear fate. While 
early stage CH+PUR treated aggregates appeared to exhibit a reduction in 
dorsal marker expression compared to aggregates treated with CH alone and an 
increase in the number of cells expressing ventral markers LFNG and OTX1, the 
neural phenotype was the more striking observation following CH+PUR 
treatment, compared to the more modest effects on dorso-ventral patterning. We 
evaluated late stage inner ear organoids (≥day 60) to see if this early stage 
phenotype impacted later stage development.  
 CH+PUR treatment was performed on early stage inner ear organoids 
cultured from human ESCs containing a GFP reporter for hair cell marker ATOH1 
(previously described in [19]). ATOH1-2A-nGFP human ESC derived aggregates 
cultured long-term produce organoids containing GFP+ cells that co-express hair 
cell marker MYO7A [19]. Derived ATOH1-2A-nGFP+ cells were also reported to 
exhibit functional capability similar to that observed in the native mouse utricle 
[19].  
 While induction of ATOH1-2A-GFP+ cells was observed in CH+PUR 
treated aggregates, the derived sensory population appeared to be reduced in 
late stage CH+PUR treated aggregates compared to aggregates treated with CH 
alone (Figure 36). Quantitative analysis is necessary to confirm whether this 
perceived reduction in ATOH1-2A-GFP induction in late stage CH+PUR treated 
aggregates is significant.  
101 
 Immunohistochemical analysis was performed to assess whether the 
derived hair cells in CH+PUR treated organoids exhibit a cochlear phenotype. 
Leiomodin 3 (LMOD3) is a marker specific to both inner and outer cochlear hair 
cells (Figure 37a), and is not expressed in vestibular sensory epithelia (Figure 
37b). Immunohistochemical analysis showed that derived hair cells from both CH 
and CH+PUR-treated aggregates did not express LMOD3 (Figure 37d). A lack of 
expression of this specific and established marker of cochlear identity appears to 
indicate that derived hair cells arising in CH+PUR treated aggregates do not 
exhibit a cochlear phenotype. Further evaluation is necessary to confirm a 
vestibular identity of these cells.  
 Immunohistochemical analysis additionally confirmed expression of neural 
marker TUBB3 (TUJ1) in both CH and CH+PUR treated organoids (Figure 38). 
Further evaluation of this late stage neuronal population is currently underway to 
determine whether the observations of an expanded neural population in early 




Figure 36: ATOH1-2A-GFP+ population appears reduced in late stage CH+PUR 
treated aggregates.  
 
DIC/FITC overlay of live day 60 ATOH1-2A-GFP derived aggregates. Day 60 CH 
treated aggregate exhibiting three ATOH1-2A-GFP+ patches. CH+PUR treated 
aggregate exhibits one ATOH1-2A-GFP+ patch. Dashed lines indicate GFP+ cell 




         
Figure 37: Late stage inner ear organoids do not express cochlear hair cell 
marker LMOD3.  
(a) Cross section of P8 mouse cochlea, Robust LMOD3 expression observed in 
both inner and outer cochlear HCs.BRN3C and ANXA4 are generic hair cell 
markers expressed in both cochlear and vestibular hair cells. (b) Cross section of 
P8 mouse utricle. Utricular tissue lacks LMOD3 expression. (c) LMOD3 
expression is not observed in Day 60 CH-treated ATOH1-2A-GFP aggregates. 
(d) Purmorphamine treated aggregates at the same time point are LMOD3-. 






Figure 38: Late stage inner ear organoids express neural marker TUJ1. 
GFP+/SOX2+ cells exhibit a hair cell-like phenotype in day 60 ATOH1-2A-nGFP 
hESC derived inner ear organoids in both CH (a) and CH+PUR (b) treated 
aggregates. TUJ1 expression is indicative of a neuronal population emerging in 




CHAPTER FOUR: DISCUSSION 
 Sensory cells of the mammalian inner ear are unable to undergo 
regeneration. Efforts have been made toward deriving inner ear sensory cells in 
vitro. The inner ear organoid model pioneered by Koehler et al (2017) uses 
human PSCs grown in 3D culture and treated with a timed series of signaling 
molecules to guide induction of otic tissue [19]. What results within this model are 
self-organized 3D structures bearing sensory hair cell-like cells that exhibit 
functional capability and bear a morphological and gene expression phenotype 
reflective of native vestibular hair cells. The goals of this dissertation were to 
investigate the source of the apparent vestibular bias within this model, and to 
evaluate a strategy for the induction of ventral otic derivatives, including cochlear 
cell types, in vitro. Focus was placed on the period of otic vesicle development, a 
time in vivo in which localized domains of gene expression are established that 
are crucial for subsequent development of the inner ear sensory structures. This 
study is the first to evaluate the patterning phenotype of human stem cell derived 
otic vesicles, and sheds light on the transcriptomic profile at this critical point of in 
vitro development. Furthermore, this work demonstrates that SHH pathway 
modulation induces changes in the patterning phenotype of the derived cell 
population, with the unexpected result of an expanded population reminiscent of 
neuroprogenitors of the cochleovestibular ganglion. This information may inform 
future inner ear organoid studies, and contribute to the realization of a more 
complete in vitro system of inner ear development.  
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 Figure 39 summarizes the key findings of the study described in 
CHAPTER 3: RESULTS. In the following chapter, I will address these findings in 
the context of my two fundamental research questions.  
 
What underlies the apparent commitment to vestibular fate within the inner 
ear organoid model?   
 In order to investigate the apparent vestibular bias within our inner ear 
model, we first employed a tool to isolate otic progenitors in early stage culture. 
The use of a PAX2-2A-nGFP human ESC reporter line served to surmount one 
of the challenges of the 3D inner ear organoid model: the heterogeneous nature 
of the stem cell-derived aggregates. While otic cell types develop in culture, the 
aggregates also contain an uncharacterized cell population that arises 
simultaneously. From a differentiation standpoint, these uncharacterized cells 
may make contributions to the aggregate “micro-environment” that are 
indispensable for otic induction. However, for evaluation of gene expression, this 
cell population may bias observations about the otic population. For example, 
dorsal otic marker DLX3 is seen to co-localize with PAX2 within inner ear 
aggregates; however, we have also observed a DLX3+/PAX2- population arising 
in the core region of the aggregates. DLX3 expression is not specific to otic cell 
types alone during development [109]. qRT-PCR analysis of whole aggregates 
would include this non-otic DLX3+ core population, and may skew the 
interpretation of DLX3 expression within the otic population. Therefore, a method  
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Figure 39: Summary of findings. 
Analysis of cell populations exposed to either WNT agonist alone (left), or with 
the addition of SHH pathway modulation (right) revealed differential expression of 
dorsal patterning markers (indicated in red), ventral patterning markers (indicated 
in blue), and neuroprogenitor markers (indicated in purple). However, not all 
dorso-ventral patterning markers were differentially expressed between the two 
treatment groups. Preliminary late stage analysis has indicated that SHH 
pathway modulated aggregates do not give rise to hair cells exhibiting a cochlear 
phenotype, and that the derived hair cell population may be reduced at the 





for purification of the presumptive otic population for gene expression analysis 
was desirable.  
 Using a PAX2-2A-nGFP human ESC reporter line allowed for monitoring 
and isolation of presumptive otic cells in live cultures. The first line of inquiry 
addressed was whether or not the PAX2-2A-nGFP+ cells arising in 3D inner ear 
culture were representative of derived otic progenitors. Many of the markers that 
define otic progenitors do not exhibit specificity solely to otic tissue; therefore it is 
necessary to compile and demonstrate expression of a battery of markers to 
support an otic phenotype. Rigorous immunohistochemical analysis of PAX2-2A-
nGFP derived aggregates showed overlapping expression of PAX2-2A-nGFP 
with otic markers PAX2 and PAX8. However, PAX2 and PAX8 are both 
expressed in kidney progenitors during fetal development [110]. Further 
immunohistochemical analysis of the expression of otic markers SOX2, FBXO2, 
and SOX10 supported the otic identity of the PAX2-2A-nGFP+ cells.  
Additionally, dorsal otic markers DLX3 and DLX5 are not observed in the 
embryonic kidney [26], nor are ventral patterning markers OTX1 and OTX2 [101]. 
Immunohistochemical analysis confirmed expression of DLX3 and OTX2 
coinciding with areas of PAX2-2A-nGFP expression, and scRNAseq analysis 
confirmed expression of all of these candidate markers among the isolated 
PAX2-2A-nGFP+ population, further supporting the otic identity of this population.  
 scRNA-seq analysis additionally allowed for the interrogation of multiple 
markers of otic development among the PAX2-2A-nGFP+ population that have 
previously proven difficult to evaluate due to limited availability of antibodies with 
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high specificity. With this analysis, we were able to evaluate for the first time the 
nature of the patterning phenotype within the derived early stage otic population. 
In vivo, the otic vesicle is patterned along a dorso-ventral axis in response to the 
action of graded signaling molecules, including WNT and SHH. Localized gene 
expression domains are key for proper morphogenesis of the inner ear sensory 
structures, with the vestibular system arising from a more dorsal region, and the 
cochlea arising from the ventralmost region.  
 Here, scRNA-seq analysis indicated mRNA expression of dorsal markers 
DLX3, DLX5, DLX6, LMX1A and WNT2B among the derived PAX2-2A-nGFP+ 
population in aggregates subjected to our established otic differentiation protocol, 
in which WNT agonist CHIR99021 (CH) is applied from day 11-18 in order to 
guide otic vesicle induction. These findings coincide with previously reported 
gene expression characterization of the dorsal otic vesicle [29-31, 76], and may 
support the hypothesis that vestibular bias may be due to a dorsalized phenotype 
of the early derived otic vesicles. This dorsalized phenotype may be the result of 
sustained exposure to WNT agonist CH during early stage culture, coinciding 
with the period of otic placode induction and subsequent otic vesicle formation. It 
is possible that dorsalization may be the result of a lack of sufficient ventralization 
signals in culture. However, it is important to note that expression of ventral 
genes OTX1, OTX2, and LFNG were also observed in CH-treated aggregates, 
albeit in a smaller percentage of cells than exhibited expression of dorsal 
markers.  
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 In order to enhance expression of ventral genes, SHH pathway 
modulation was applied during culture, and will be discussed in the subsequent 
section, along with an expanded interpretation of dorsal gene expression in CH 
treated aggregates relative to those receiving SHH pathway modulation.  
 
What factors may be applied in order to guide differentiation of otic 
progenitors toward a cochlear fate?  
 In this investigation, focus was placed specifically on SHH pathway 
modulation as a strategy for cochlear cell differentiation, due to the role of SHH in 
ventral patterning and subsequent cochlear induction [29, 31]. Alternate 
strategies for guiding cochlear development in vitro, including the investigation of 
additional signaling pathways, will be discussed more extensively in CHAPTER 
FIVE: FUTURE DIRECTIONS.  
 We found that dual treatment of CH and SHH pathway agonist PUR 
during early stage culture led to a size phenotype compared to control treated 
aggregates receiving CH alone, with the CH+PUR-treated aggregates growing 
significantly larger. This could be indicative of increased proliferation, which 
corresponds to the role of SHH as a mitogen [71]. Additionally, the trend toward 
an increased PAX2+ population in CH+PUR treated aggregates, as assessed by 
immunohistochemistry and FACS, may indicate enriched otic progenitor 
formation. This may be due to increased proliferation overall, or indicative of the 
promotion of ventralization in the derived aggregates, as PAX2 is initially broadly 
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expressed in the early otic epithelium but becomes restricted to the ventral 
domain during otic vesicle maturation [82].    
 scRNA-seq analysis provided insight into the transcriptomic profiles of 
isolated PAX2-2A-nGFP+ population subjected to CH+PUR treatment during otic 
vesicle development. We evaluated expression of PTCH1 and GLI1, SHH 
pathway components that are both regulated by the SHH signaling pathway [99, 
100]. The CH+PUR treated population was found to contain a significantly larger 
population of cells expressing SHH receptor PTCH1 compared to cells treated 
with CH alone. The trend with respect to SHH pathway effector GLI1 was similar 
but not significant across three replicate datasets. In general, the observations 
between the two treatment groups appear to indicate that SHH pathway 
activation is occurring within the CH+PUR treated aggregates. 
 Single-cell analysis was additionally used to interrogate the patterning 
phenotype of the CH+PUR treated population. A significantly higher percentage 
of CH+PUR treated cells exhibited expression of ventral markers LFNG and 
OTX1 compared to cells treated with CH alone. Unlike LFNG and OTX1, ventral 
marker OTX2 appeared to be expressed in a higher number of cells in CH-
treated samples compared to those treated with CH+PUR. It should be noted that 
while OTX1 and OTX2 exhibit overlapping expression in the in vivo otic vesicle, 
they does not overlap entirely [101]. Furthermore, OTX1 and OTX2 expression 
may be controlled by independent mechanisms. In a study from Riccomagno et 
al, inner ears of mice exhibiting ectopic expression of SHH in the dorsal region of 
the otic epithelium were evaluated to determine whether overexpression of SHH 
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is sufficient to ventralize the otic vesicle [29]. Expanded expression of several 
ventral markers into the dorsal otic vesicle was observed in these mice, along 
with a reduction in dorsal marker expression. However, OTX2 expression was 
unaffected by ectopic Shh signaling, maintaining localization to the ventralmost 
region of the otic vesicle. This finding implied that OTX2 may not be directly 
regulated by Shh, or that additional signals may be required in order to activate 
OTX2 expression. Within our scRNA-seq datasets, SHH pathway modulation did 
not appear to influence OTX2 expression. Taken with the observation that the 
overall number of OTX2-expressing cells is low in both treatment groups, it is 
possible that in both conditions a key signaling pathway may be missing in order 
to induce expression of OTX2.   
  In general, the percentage of cells expressing ventral markers LFNG and 
OTX1 was increased in the CH+PUR treated population compared to the CH 
population, but still modest, representing less than 9% of CH+PUR treated cells 
and less than 2% of CH treated cells for LFNG, and less than 6% of CH+PUR 
treated cells and less than 1% of CH treated cells for OTX1. These results 
appear to indicate that while CH+PUR treatment may induce a minor 
ventralization effect, it is not sufficient to induce a more robust gene expression 
phenotype across the population as a whole. 
 However, the observations with respect to dorsal markers appeared more 
substantial; there was a significant reduction in the number of cells expressing 
dorsal markers DLX3, WNT2B, and LMX1A in the CH+PUR treated population 
compared to the population treated with CH alone. The size of the population 
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expressing additional dorsal markers DLX5 and DLX6 was not significantly 
different between the two treatment groups; this observation will be addressed 
further in the context of late stage analysis. Nonetheless, the decrease in several 
key dorsal markers in the CH+PUR treatment group, taken together with the 
evaluation of ventral marker expression, may imply that SHH pathway 
modulation is sufficient to reduce dorsalization within the derived otic progenitor 
population to some extent, but insufficient to substantially increase expression of 
ventral genes.  
 The most striking finding within our analysis was the expansion of a neural 
progenitor population in the CH+PUR treated cells, indicated by a significantly 
higher percentage of cells expressing neuroprogenitor markers NEUROG1 and 
NEUROD1, which are found in precursors to cells of the cochleovestibular 
ganglion [104, 111, 112]. This was an unanticipated result, but coincides with the 
role of SHH pathway in neural patterning of the inner ear at this stage of 
development [29, 31]. Temporal analysis of day 15 and day 20 CH+PUR treated 
populations revealed a more robust NEUROG1+ population at day 15 compared 
to day 20, seemingly mirroring in vivo observations that NEUROG1 expression 
precedes NEUROD1 in developing inner ear neuroblasts [104]. Expansion of the 
NEUROD1-expressing population was observed from day 15 to day 20, further 
reflecting the in vivo progression of inner ear neural development [104, 111]. 
Comparative analysis of otic marker expression between the CH and CH+PUR 
populations additionally revealed that the CH+PUR population exhibited a 
significantly higher percentage of cells expressing transcription factor SOX2, 
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which is expressed in both sensory and non-sensory otic cell types, and 
functions in inner ear neurogenesis [96, 113]. 
 Roccio and colleagues recently performed microarray analysis of 
microdissected SGNs from human fetal tissue at several time points [76]. Within 
our datasets, the stem cell derived presumptive neural populations of both 
treatment groups exhibiting expression of NEUROD1, NEUROG1, and neural 
marker ISL1 is similar to the phenotype observed in week 9 to week 11 human 
fetal SGNs [76]. Expression of additional neural markers POU4F1, TUBB3, and 
NEFL among the presumptive neural populations further supported a neural 
identity, while additional expression of markers of SGN and VGN development 
appeared to support an early neuronal phenotype specific to neurons of the inner 
ear. Expression of these markers appeared consistently expanded within the 
CH+PUR treated population compared to the CH-treated population, which 
exhibited a more restricted neural population. Altogether, these results indicate a 
presumptive neural population in both treatment groups similar to that of the 
neuroprogenitors that give rise to spiral and vestibular ganglion neurons. 
Additionally, the expanded neural population observed among the CH+PUR 
treated cells may indicate that SHH pathway modulation in early stage inner ear 
organoid culture serves to bias differentiation toward a neural as opposed to an 
epithelial fate.  
 Preliminary late stage analysis of SHH pathway modulated aggregates 
has indicated a decreased hair cell population compared to aggregates treated 
with CH alone during otic vesicle induction. It is possible that hair cell 
115 
differentiation has been minimized as a result of the expanded neuroprogenitor 
population at the otic vesicle stage in CH+PUR treated aggregates. Neural cell 
types have previously been observed within our culture model arising alongside 
the derived inner ear hair cell population [19]. However, this population has not 
yet been characterized to confirm whether these cells are representative of inner 
ear neurons, or indicative of other neural cell types. The observations of a 
neuroprogenitor population in early stage culture reminiscent of inner ear 
neuroblasts potentially provide support for otic identity in late stage neurons. 
Interrogation of SGN and VGN markers at the late stage of culture would be 
necessary to characterize this derived neural population. Additionally, 
quantitative analysis would be beneficial to confirm whether the early stage 
phenotype of an expanded neural population in CH+PUR treated aggregates 
correlates with an expanded neural population in late stage cultures.  
 It is important to note that the derived hair cells in CH+PUR treated 
cultures do not express cochlear hair cell marker LMOD3. Further analysis is 
necessary to confirm a vestibular phenotype in these cells, but this preliminary 
observation indicates that a cochlear identity has not been achieved as a result 
of our current SHH treatment paradigm. This could be owing to several 
possibilities. One potential reason may be related to the expression of dorsal 
markers DLX5 and DLX6 observed in both the CH and CH+PUR treated 
populations via scRNA-seq comparative analysis in early stage culture. Unlike 
the other dorsal markers surveyed, the percentages of cells expressing DLX5 
and DLX6 were not statistically significant between the two treatment groups. 
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Notably, DLX5 was expressed in an average of 28% of CH treated cells and 26% 
of CH+PUR treated cells, exhibiting the highest representation of all the dorsal 
markers evaluated across both datasets. Dlx5-/-/Dlx6-/- double mutant mice fail to 
form vestibular structures [114], and a similar effect is observed in Wnt1-/-/Wnt3a-
/- knockout mice, wherein no vestibular components arise, coinciding with a loss 
of Dlx5 and Dlx6 expression in the dorsal otic vesicle [30]. Expression of these 
dorsal markers therefore appears indispensable for vestibular structure 
formation. Our observations that the expression of DLX5 and DLX6 is unaffected 
by SHH pathway modulation raises the possibility that these factors may be more 
directly responsible for maintaining vestibular fate within our model than the other 
dorsal factors evaluated, including DLX3, WNT2B, and LMX1A, that did exhibit 
significant reduction following SHH pathway modulation. Riccomagno and 
colleagues demonstrated that DLX5 and DLX6 expression in the otic vesicle is 
dependent on Wnt signaling, but is regulated in larger context by the interplay 
between Wnt and Shh signaling pathways acting on the developing otocyst [30]. 
The concerted efforts of these two pathways in dorso-ventral patterning of the 
inner ear is complex, and it appears that each pathway may regulate markers of 
regional identity in different ways [115]. Within our model, the current CH+PUR 
treatment strategy may not accurately reflect the balance of signals needed to 
sufficiently reduce dorsalization and induce ventralization to an extent permissive 
to cochlear cell induction. Further strategies to refine this treatment, along with 
alternate strategies for cochlear cell differentiation, are discussed in CHAPTER 
FIVE: FUTURE DIRECTIONS.   
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 Another possibility underlying the apparent vestibular bias within our 
model is that the current length of culture is simply insufficient to observe 
cochlear cell types.  In human embryological development, formation of the 
vestibular organs and sensory populations occurs prior to cochlear development 
[76]. Cochlear hair cell differentiation occurs between weeks 11-12 in human 
development, with MYO7A+ cells observed in the vestibular sensory epithelium 
by weeks 8-9. A potential gap in the analysis of the CH+PUR treatment in human 
inner ear organoids is the time span—here, CH+PUR aggregates were cultured 
for up to 70 days only. Maintenance of inner ear aggregates in culture has 
previously been demonstrated for up to 150 days [19]. It is possible that culturing 
aggregates for a longer time period may lead to the induction of cochlear hair 
cells naturally, as cochlear hair cell induction succeeds vestibular hair cell 
development in vivo.  
  
118 
CHAPTER FIVE: FUTURE DIRECTIONS 
 This study has provided valuable insight into the gene expression 
phenotype of the presumptive otic progenitor population from early stage human 
ESC-derived inner ear organoids. Additionally, this work has shed light on the 
differential gene expression occurring in response to SHH pathway modulation 
within this model. SHH treatment was pursued as a potential strategy for 
inducing a patterning phenotype permissive to cochlear induction in vitro. While 
treatment with SHH pathway agonist PUR was shown to reduce expression of 
select markers local to the vestibular-yielding dorsal otic vesicle, upregulation of 
ventral genes was modest. More strikingly, a phenotype indicative of a 
neuroprogenitor population indicated that SHH pathway modulation in early stage 
inner ear organoid culture may bias differentiation toward a neural lineage at the 
expense of an epithelial lineage. Strategies to further investigate these findings, 
along with strategies to further enrich ventral gene expression and induce 
cochlear cell types, will be discussed in this chapter.  
 
Improving efficiency of otic induction 
 One of the limitations of the human inner ear organoid system remains the 
efficiency of otic induction. FACS analysis has shown that generation of 
presumptive otic progenitors, as defined by PAX2-2A-nGFP expression, appears 
to be ~5% of the total cell population in conventionally treated aggregates (CH 
treatment from day 11-18). FACS of late stage ATOH1-2A-GFP aggregates 
stained for epithelial marker EPCAM (expressed in supporting and sensory cell 
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populations) yielded less than 4% of the total cell population, indicative of both 
sensory and non-sensory otic cells (data not shown). Treatment with SHH 
pathway agonist PUR increases the size of the PAX2-2A-nGFP+ population in 
early stage culture, but this appears to occur at the expense of late stage 
induction of sensory hair cells.  
 Optimization is necessary to increase the overall efficiency of otic 
induction and subsequent induction of sensory cell types within the inner ear 
organoid model. This will increase the utility of this system as a platform for high-
throughput drug screening, drug design, or otic toxicity studies. A study from Wu 
et al investigated a strategy to reduce off-target cell types in an organoid model 
of human kidney development [116], wherein small molecule inhibition of BDNF 
receptor NTRK2 resulted in a 90% decrease in unwanted neuronal cell types 
observed in culture. A similar strategy may potentially be employed to improve 
efficiency of otic induction by reducing off-target differentiation; factors within the 
scRNA-seq datasets generated here may be identified and targeted with small 
molecule treatment in culture to decrease off-target cell induction and therefore 
lead to enriched otic differentiation.  
 Optimization of small molecule treatments during the first eight days of 
culture may also lead to increased otic induction. Successive inhibition of BMP 
and WNT pathways along with FGF activation has been shown to lead to the 
specification of the pre-placodal region [117]. Within our model, aggregates are 
treated with BMP inhibitor LDN and with FGF-2 on culture day 4 to this purpose. 
We have not explored the effects of additional WNT inhibition at this timepoint 
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[20, 118]. Adding WNT inhibitor within the first eight days of culture may lead to 
more efficient induction of the pre-placodal region, which may then lead to 
enriched otic induction at later stages of culture. 
 
Toward cochlear differentiation  
 While SHH treatment was shown to induce changes in the patterning 
phenotype of early stage derived otic progenitors, late stage analysis did not 
confirm the induction of cochlear cell types. Proposed here are several potential 
strategies to continue the pursuit of cochlear induction within our inner ear model.   
 
Fine-tuning SHH pathway modulation  
 In vivo, SHH is secreted from the floor plate and notochord and acts on 
the developing otic vesicle in a graded manner [115]. One of the limitations of 
treating aggregates with a small molecule agonist for SHH pathway activation is 
that it is a broad, untargeted treatment. A possible avenue of investigation would 
be to attempt to model the SHH gradient observed in vivo within the culture 
model. Embedding early stage aggregates in Matrigel and co-culturing with 
beads coated in PUR or another SHH pathway activator may serve to better 
mimic the in vivo environment, in which a gradient of SHH signaling acts on the 
developing otic vesicle. Enacting SHH treatment in a more nuanced manner may 
result in a phenotype reflecting both neural induction and ventralization. 
Furthermore, as opposing gradients of SHH and WNT act on the developing otic 
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vesicle in vivo [29, 30, 119, 120], it may be beneficial to co-culture with both SHH 
pathway and WNT signaling agonists in a regionalized manner.  
 Additionally, this study investigated the application of small molecule 
agonist PUR for SHH pathway activation in culture. Alternate small molecules for 
SHH signaling activation may be evaluated, including SAG and GSA-10 [121, 
122], to determine whether the effects are specific to PUR treatment, or 
consistent with other small molecules. PUR, SAG, and GSA-10 all act as 
agonists for SHH pathway effector SMO. The application of SHH recombinant 
protein in culture may also be investigated, to evaluate the effects of eliciting 
SHH signaling activation via a different pathway component.  
  
Additional pathway modulation 
 WNT signaling has been shown to function in specification of dorsal otic 
fates, contributing to the prevailing model that opposing gradients of WNT and 
SHH signals from the hindbrain are responsible for specification of dorsal and 
ventral gene expression domains within the developing otic vesicle [29, 30, 119, 
120]. We have shown that aggregates that receive WNT agonist CH along with 
SHH pathway agonist PUR during the otic vesicle induction stage appear to 
express markers of the dorsal otic vesicle in a lower relative number of cells 
compared to aggregates receiving WNT modulation alone at the same stage. 
While SHH pathway modulation appears to induce a modest enrichment of 
ventral markers, it is possible that subsequent WNT inhibition following SHH 
pathway treatment may serve to further ventralize the derived otic vesicles. 
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Treatment with SHH pathway agonist PUR alone during otic vesicle induction 
appears to negatively impact otic vesicle formation. Therefore, initial treatment 
with WNT agonist appears to be indispensable for otic vesicle formation within 
this model. However, application of WNT inhibitor subsequent to CH+PUR 
treatment may allow for otic vesicle formation, but may further promote 
ventralization necessary for cochlear induction.   
 BMP signaling has additionally been implicated in dorsal patterning of the 
otic vesicle [115, 123]. The human inner ear aggregates are thought to exhibit a 
certain degree of endogenous BMP signaling, as evidenced by the variable BMP 
treatment necessary for non-neural ectoderm induction across different human 
pluripotent stem cell lines [19]. Aggregates of human WA25 ESCs do not require 
BMP treatment in early stage culture, whereas aggregates cultured from mND2-0 
human iPSCs required BMP treatment in order to exhibit non-neural ectoderm 
induction [19]. It stands to reason that a degree of endogenous BMP signaling 
may be at play in otic vesicle stage culture as well, but this has yet to be 
assessed. Due to the contribution of BMP in dorsal otic vesicle patterning, it is 
possible that the introduction of BMP inhibition during otic vesicle induction in 
vitro may additionally serve to reduce dorsalization of the derived otic population, 
and thereby promote ventral otic fates.   
  
The potential impact of the in vivo microenvironment  
 As in all in vitro studies, the contributions of the in vivo microenvironment 
cannot be ignored. It is possible that small molecule treatments alone, no matter 
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how nuanced the delivery, are insufficient for induction of cochlear cell types in 
vitro. The coordinated effects of signaling pathways in vivo may be so complex 
that the correct “cocktail” of signaling molecules cannot be fully comprehended 
for precise cochlear induction in vitro. Implanting derived otic progenitors into the 
embryonic mouse inner ear may provide the missing cues necessary for cochlear 
differentiation, and would further serve to validate the otic identity and 
differentiation capacity of these derived cells.  
 
Assessing late stage neural identity 
 Further analysis to determine the identity of the late stage neural 
population in CH+PUR treated aggregates will be key to confirming whether the 
derived inner ear neuroprogenitor population observed in early stage cultures is 
capable of giving rise to cells of SGN and/or VGN identity. Previous efforts to 
derive inner ear neurons in vitro have employed stepwise differentiation methods 
driven by the manipulation of signaling pathways implicated in neural 
development [51, 124, 125]. Transient expression of Neurog1 [126], exposure to 
human fetal auditory neuron conditioned media [127], and co-culture with 
auditory neuron explants [128] have also been investigated as strategies for 
inner ear neuron differentiation. Among these studies, SHH signaling has been 
largely ignored as a strategy for auditory and vestibular neuron induction, and 2D 
culture has served as the prevalent format for differentiation. Our system offers 
the advantage of concurrently arising hair cell and neuronal populations, and a 
degree of self-organization that more closely mimics in vivo inner ear 
124 
development. The neuroprogenitor population identified within our early stage 
culture appears to be a promising foundation to support inner ear neural 
induction within our system. Immunohistochemical analysis of inner ear neural 
markers, as well as evaluation of the functional capability of this population 
through electrophysiological analysis, would be appropriate next steps to confirm 
the identity of the late stage derived neuronal population. 
 The presence of a verified inner ear neuron population within our model 
would serve to enhance the complexity of the system, thereby bolstering its 
applicability in future inner ear studies as a more complete representation of the 
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